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ABSTRACT 
GENES DIFFERENTIALLY EXPRESSED AT 1 DAY, 6 WEEKS, AND 6 
MONTHS OF AGE IN AORTAS OF SPONTANEOUSLY ATHEROSCLEROTIC 
WHITE CARNEAU PIGEONS 
By 
Suzanne Lee Pearlman 
University of New Hampshire, May, 2011 
Genetics is reported to be the primary causative factor for individuals diagnosed 
with atherosclerosis, in the absence of known risk factors. The development of 
atherosclerosis in White Carneau (WC) pigeons is of genetic origin, making it an 
excellent model to study genetic factors. 
Representational Difference Analysis (RDA) was used to determine genes 
differentially upregulated between three ages, at the celiac bifurcation of the aorta in WC 
pigeons. Genes responsible for spontaneous initiation of atherosclerosis were 
hypothesized as being differentially expressed at 1 day, while those differentially 
expressed at 6 weeks and 6 months were related to progression. 
Multiple candidate genes were upregulated at 1 day, although they were not 
definitively assigned to initiation. Genes upregulated at 6 weeks reflected increases in 
protein synthesis, loss of cellular integrity, and changes in muscle contraction. By 6 
months, increases in lipid metabolism and changes in energy metabolism from oxidative 
phosphorylation to glycolysis were apparent. 
xi 
INTRODUCTION 
Atherosclerotic heart disease continues to be the number one cause of morbidity 
and mortality in the United States and other developed countries (1, 2). Atherosclerosis is a 
chronic multifactorial disease that results from both environmental and genetic factors, as 
well as their interactions (3-5). Diet, lack of exercise, high blood cholesterol levels, 
smoking, gender, and high blood pressure are known risk factors that contribute to 
approximately half of the cases in the United States (1, 2, 6). Upon clinical diagnosis of 
the disease, treatments modifying these factors are successful in only about 50 % of the 
cases (1). There is a dichotomy here because many people who have some or all of these 
known risk factors never develop atherosclerosis (1), while others who do develop 
atherosclerosis never exhibit any of these known risk factors. Heritability studies reveal an 
increased familial relationship for death from coronary heart disease. Interestingly, 
monozygotic twins have an even greater risk than dizygotic twins, suggesting a strong 
genetic component (7). 
Heredity is therefore becoming more widely accepted as the underlying factor, 
particularly in those individuals who do not respond to prevention or treatment strategies, 
which focus on risk factor modification (1-3, 8, 9). Unfortunately, current research has not 
been successful in identifying the underlying human genetic factors that contribute to the 
development of atherosclerotic lesions. In addition, research conducted on humans is 
difficult due to ethical issues. This emphasizes the need for using animal models, 
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particularly those that exhibit atherosclerotic development similar to that observed in 
human cases. 
White Carneau (WC) pigeons have been used for many years to study 
atherosclerosis and are an appropriate model for multiple reasons (8, 10-12). In the WC 
pigeon, lesions occur at branch points along the aorta, and progress into full blown plaques 
which pose a striking resemblance to those found in humans (8, 10-14). Also, the 
development of atherosclerosis in WC pigeons occurs spontaneously (non-induced) in the 
absence of any known risk factors (8, 10, 12) making it easier to identify underlying 
genetic components. In contrast, the Show Racer (SR) pigeon is resistant to the disease, 
providing an experimental control to compare differences in genetic expression (8). 
Research also shows that atherosclerosis in the WC pigeon is inherited as a single-gene, 
autosomal recessive trait (15) potentially facilitating efforts to identify the gene responsible 
for the disease in pigeons. Once the gene contributing to atherosclerosis in the WC pigeon 
is identified, it can then be compared with the human genome to assist in understanding the 
mechanisms responsible for atherosclerosis in humans. 
While the precise mechanisms of initiation and progression of atherosclerosis are 
not clear in humans, biochemical changes in the aorta of WC pigeons occur by 6 weeks of 
age while morphological changes are observed by 6 months of age (2, 16, 17). These 
predictable changes provide specific time-frames in which to search for genetic changes in 
the WC pigeon to better understand stages of lesion development. Comparing the 
differential expression between these ages in the WC pigeon will help to distinguish genes 
responsible for initiation and progression of atherosclerosis. 
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Representational Difference Analysis (RDA) was developed to identify 
differentially expressed genes between two similar populations (18). This method couples 
Subtractive Hybridization (SH) with Polymerase Chain Reaction (PCR), to exponentially 
amplify only those genes that are differentially expressed between two similar populations. 
Compared to other methods, isolation of genes using RDA is both cost effective and 
efficient in a small laboratory setting, when the genome under investigation (pigeon) has 
not yet been characterized (18, 19). RDA has the potential to capture unknown genes even 
when expressed in low copy number. Once these genes are sequenced, they can be 
identified by comparing them with known sequences of other species due to genetic 
homology (18). This work described herein utilized RDA to identify genes differentially 
upregulated in the WC pigeon at ages known to reflect biochemical and morphological 
changes associated with atherosclerosis. 
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CHAPTERI 
REVIEW of LITERATURE 
Human Atherosclerosis 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in the 
United States with atherosclerosis being the primary cause of this pathology (20-23). It is 
estimated that one in three adults has CVD, which on average translates into one death 
every 37 seconds from that cause (24). Atherosclerosis is considered a chronic 
multifactorial disease (25) caused by individual environmental and genetic factors, as well 
as synergistic environmental and genetic interactions (3-5). Chronic multifactorial diseases 
collectively account for the greatest burden on health care services in the U.S. (26). 
Multiple risk factors associated with the clinical expression of atherosclerosis 
include age, gender, hypertension, hypercholesterolemia, diabetes, obesity, smoking, lack 
of physical activity, and stress (22, 27, 28). These risk factors alone, however, cannot 
always account for the development of atherosclerosis (20). Many individuals who develop 
atherosclerosis do so in the absence of any of these known risk factors. In fact, 
approximately 50% of men and women who die suddenly from this disease have no 
obvious risk factors or prior symptoms (24). For example, many individuals who have 
what are considered healthy cholesterol levels, still suffer heart attacks (29). 
Adding to the complexity, often people who have some or all of these known risk 
factors never develop clinical atherosclerosis (1, 30). Once diagnosis of the disease is 
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made, however, treatments used to modify these factors are only successful in 
approximately 50% or less of the cases (1, 30). 
In spite of the fact that millions of dollars have already been spent to study 
atherosclerosis, little is known about the early mechanism(s) of this disease (31). One 
explanation is that the ability to distinguish between lesion initiation and progression 
continues to elude current research. Another issue is that atherosclerosis in humans 
develops very slowly, and at different rates depending on the individual, making it difficult 
to map out a consistent pattern. In addition, humans develop a thickened intima before 
clinical "atherosclerosis" presents itself, and there has been much disagreement whether 
this thickened intima is actually the precursor or earliest stage of the disease. There are 
further questions of whether or not the accumulation of extracellular proteoglycans and 
lipid precede the infiltration of macrophage cells (31). Given that atherosclerosis is a 
chronic disease exhibiting many multifactorial contributions there is a surprising shortage 
of information dealing with the earliest stages of atherogenesis (28). 
Post-mortem studies are helpful in that they provide evidence of the sub-clinical 
stages of atherosclerosis, revealing visible lesions, that often do not manifest clinically until 
the third or fourth decade of life (20, 29). These visible manifestations are considered the 
earliest stage of atherosclerosis and present as foam cells or fatty streaks due to the 
collection of lipid droplets within the cytoplasm of cells (22). 
Autopsies conducted from 1987 - 1994 on victims who died from accidents 
revealed that atherosclerosis begins in youth (32). Strong et al., found that intimal lesions 
were present in all aortas, and in more than half of the right coronary arteries of 15 - 19 
year olds with increasing prevalence and extent through 30 - 34 years of age. They also 
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found that all the age groups contained fatty streaks in their aortas while fibrous plaques 
appeared in coronary arteries of only a few individuals under the age of 20 (32). The 
researchers concluded that while fatty streaks are usually innocuous, if they persist, and in 
the presence of specific conditions, they can progress to the clinical disease state (32). 
Additional human autopsies reveal that some regions in the vessel wall have a propensity 
for early atherosclerotic lesions while others are resistant (11). These same autopsies also 
reveal a very distinct pattern in the distribution of early atherosclerotic lesions, which is in 
agreement with Caro's low sheer stress theory (11). 
Stary's work supports the research conducted on these autopsies and states, while 
advanced lesions may result in clinical symptoms, the early lesions that pave the way are 
silent (33). Given these findings, it is essential to understand the earliest molecular and 
cellular mechanisms responsible for atherosclerotic development in order to establish 
approaches that will delay onset as well as progression of the disease before it produces 
adverse clinical outcomes (34). 
Additional histological studies of coronary arteries from human autopsies of various 
ages, from infants to adults, demonstrate regions that are susceptible to atherosclerosis are 
abundant in smooth muscle cells (SMCs), while regions that are resistant to its 
development contain very few SMCs (33-35). Some animal experiments also demonstrate 
that SMCs are integral components that increase during the initial stage of lesion formation 
(33). Studies also show that intimal SMCs express lower levels of proteins associated with 
contractile function, and have an increased capacity for producing extracellular matrix, 
proteases and cytokines, compared with medial SMCs (34, 36, 37). In addition, intimal 
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SMCs, also known as synthetic SMCs have a higher proliferative index, and can synthesize 
up to 46 times more collagen than medial (contractile) SMCs (34, 36-38). 
Until recently, it has not been clear whether extracellular lipid and proteoglycan 
accumulation, occurs before macrophage infiltration in the human disease (31). It is 
suggested that SMCs play a key role in initiation and early progression of atherosclerosis, 
since alterations of their extracellular matrix can cause SMCs to proliferate and increase 
their lipid content (31,33). This lipid accumulation by SMCs then contributes to foam cell 
formation in a pattern that is analogous to the pattern observed with macrophages, which is 
believed to then accelerate the formation of lesions (34, 39). 
It is now widely agreed that the SMCs of human atherosclerotic lesions originate 
from the medial layer and that most of these intimal SMCs contain lipid droplets (33). One 
of the challenges with determining which cell type is ultimately responsible for lesion 
development and progression is that many of the functions that are attributable to SMCs 
during early lesion development are known to occur in other cell types such as 
macrophages (34). 
The current paradigm as laid out by the American Heart Association (AHA) (Table 
1) proposes an orderly, linear pattern of lesion development where an initial lesion or fatty 
streak progresses into an advanced lesion (40). 
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Table 1: Current AHA Classification 
Current AHA Classification 
Terms for Atherosclerotic Lesions According 
to Histological Classification 
Type I lesion 
Type Ila lesion 
Type lib lesion 
Type III lesion 
Type IV lesion 
Type Va lesion 
Type Vb lesion 
Type Vc lesion 
Type VI lesion 
Initial lesion 
Progression-prone type II 
lesion 





Fibroatheroma (type V 
lesion) 
Calcific lesion (type VII 
lesion) 
Fibrotic lesion (type VIII) 
Lesion with surface defect 
and/or 
hematoma/hemorrhage 
and/or thrombotic deposit 
Other Terms for the Same Lesions Often Based on 
Appearance to the Unaided Eye 
Fatty dot or streak 
Fatty dot or streak 
Fatty dot or streak 
Atheromatous plaque, fibrolipid 
plaque, fibrousplaque, plaque 
Atheromatous plaque, fibrolipid 



















Studies used to formulate this paradigm were conducted on animals. One of the 
problems with this is that lesions in induced animal models differ from lesions found in 
humans (31, 32, 40). To complicate matters further, lesions from human autopsy studies 
demonstrated a wide array of morphological variations that are not entirely consistent with 
the current AHA paradigm (40). Work by Virmani et al., found that there is insufficient 
direct experimental evidence from humans and animal models to clearly explain lesion 
formation and progression as laid out by the AHA (40). Nakashima also found that the 
morphological features of early atherosclerosis differ between humans and animal models 
(31). For example, the site of lipid deposition differs between animals and humans (41). 
He found that the narrow subendothelial space was the site of lipid deposition in animal 
models unlike in humans where the earliest lipid deposits occurred in the deep layer of the 
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thickened intima (31). As a result, Virmani et al., devised a more thorough classification 
(Table 2) that is consistent with the AHA paradigm, yet which more accurately classifies 
the morphological variations that exist in such models of atherosclerotic research (40). 
Table #2: Virmani's Modified AHA Characterization 
Modified AHA Classification Based on Morphological Description 
Nonatherosclerotic intimal lesions 
Intimal thickening 
(prone) 
Intimal xanthoma, or 
"fatty streak" 
(resistant) 
The normal accumulation of smooth muscle cells 
(SMCs) in the intima in the absence of lipid or 
macrophage foam cells 
Luminal accumulation of foam cells without a necrotic 
core or fibrous cap. Based on animal and human data, 
such lesions usually regress. 
Thrombus absent 
Thrombus absent 




Fibrous cap atheroma 
Erosion 





SMCs in a proteoglycan-rich matrix with areas of 
extracellular lipid accumulation without necrosis 
Luminal thrombosis; plaque same as above 
Well-formed necrotic core with an overlying fibrous 
cap 
Luminal thrombosis; plaque same as above; no 
communication of thrombus with necrotic core 
A thin fibrous cap infiltrated by macrophages and 
lymphocytes with rare SMCs and an underlying 
necrotic core 
Fibroatheroma with cap disruption; luminal thrombus 
communicates with the underlying necrotic core 
Eruptive nodular calcification with underlying 
fibrocalcific plaque 
Collagen-rich plaque with significant stenosis usually 
contains large areas of calcification with few 
inflammatory cells; a necrotic core may be present 
Thrombus absent 
Thrombus mostly 




mural and infrequently 
occlusive 









Virmani reorganized the AHA classification of type I and II lesions as non-
atherosclerotic, intimal xanthomas that do not develop into progressive atherosclerotic 
lesions in animal models (40). He also found that intimal xanthomas are consistently 
prevalent in all populations especially when exposed to a Western diet (40). According to 
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human, as well as animal studies, intimal xanthomas usually regress. On the other hand, 
intimal thickenings include SMCs that are clonal in nature which can readily progress to 
"pathological" intimal thickenings that include a proteoglycan rich matrix along with some 
areas of extracellular lipid accumulation (40). Intimal lesions are characterized by the 
infiltration of mononuclear cells in the absence of foam cells thus outlining the earliest 
stage of atherosclerotic lesion development (28). Doran et al., found that SMCs are the 
first cells present at sites destined to develop into atherosclerotic lesions (34). Recent 
studies reveal that intimal thickenings are in fact the precursors for advanced 
atherosclerotic lesions and that intimal proteoglycans are actively involved in the disease 
process of atherosclerosis in humans (31, 41, 42). 
While human and animal models contribute to the understanding and 
characterization of the morphological features that present in early atherosclerosis, they 
raise many more questions regarding the underlying pathology of the disease. Challenging 
these classifications, however, will provide a valuable framework from which to develop a 
more complete understanding of the processes involved in this complex multifactorial 
disease (22). 
Research thus far, emphasizes the need to look deeper to explore the genetic 
factors that contribute to susceptibility to atherosclerosis in some individuals while others 
maintain resistance (21). Collectively, clinical genetic studies have established that genetic 
factors do play a major role in susceptibility to atherosclerosis (5), but because of the 
phenotypic complexity of atherosclerosis in humans it has been increasingly difficult to 
characterize genetic mechanisms responsible for the disease (15). While examining 
heritability of atherosclerosis in both family and twin studies, inheritance was a reliable 
10 
factor for determining atherosclerotic risk, in most cases exceeding 50% of those evaluated 
(43). This was further demonstrated in a study by Marenberg et al., which found the 
concordance rate among monozygotic twins to be twice as high 
(8.1:3.8 <$\ 15:2.6 $, with a 95% confidence interval) as that of dizygotic twins (7). 
Given this understanding, atherosclerosis does not behave like a single gene 
Mendelian disease (5). In general, atherosclerosis in humans is believed to be a complex 
polygenic disorder that results from a combination of numerous genes and environmental 
factors (5). In addition, atherosclerosis is also a heterogeneous disease in that different 
individuals express various manifestations of the disease with respect to genetic and 
environmental contributions (5, 30, 43). As a result, understanding the various contributing 
factors of the disease may determine the therapy or therapies best suited to treat it (43). 
Understanding Mendelian diseases and known Mendelian forms of atherosclerosis could 
also provide an understanding into the pathogenesis of common non-Mendelian forms of 
atherosclerosis (5). 
Familial Hypercholesterolemia (FH) and Tangier disease are primary examples of 
how studying Mendelian disorders have contributed to the effective treatment and 
understanding of monogenic diseases (43) that ultimately lead to atherosclerotic 
complications (5). The study of FH has also contributed to the determination of the 
molecular pathways that regulate cholesterol metabolism, thus leading to drug treatment for 
many individuals affected by this major risk factor, associated with atherosclerosis (43, 44). 
It is thus becoming increasingly clear that understanding the role of inheritance is crucial to 
be able to reduce mortality from this disease. In order to effectively identify genetic factors 
responsible for atherosclerosis, it will be necessary to incorporate complementary 
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approaches such as the use of animal models that facilitate functional genetic experiments 
(43). When it comes to candidate genes, Mendelian diseases provide a logical basis for the 
study of atherosclerosis (43). Many candidate genes have already been identified, but 
because of the multiple factors implicated in human atherosclerosis, it is difficult to directly 
examine the role of these genes (43, 44). Consequently, there has been limited success in 
providing reliable explanations for disease susceptibility (3). Because atherosclerosis 
involves the interactions between arterial cells, blood elements, and genetic factors acting 
at the level of the arterial wall, each of these may likely influence the genetic regulation of 
susceptibility to the disease process (43, 45). In addition, the heterogeneity of human 
populations, as well as the growing likelihood that many genes are involved in the disease 
process, makes it increasingly challenging to identify genes involved in atherosclerosis (3). 
For these reasons, animal models can be particularly useful to identify genes, that may be 
involved in human atherosclerosis (43). 
Pigeon Models 
When selecting an animal model it is essential to choose one that best approximates 
the pathophysiology of the disease in humans (4). It is also important, whenever possible, 
to choose a model that is low in cost, provides ease of housing, is manageable in size, 
breeds relatively quickly and easily, and has a well-defined genetic background (4). 
Specifically, when selecting a model, one needs to look for a model that develops 
atherosclerotic lesions in a pattern similar to that in humans as described in previous 
autopsies, and histology reports. 
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There is no one model that meets all these criteria when designing an experiment; 
therefore, one must select the best model given the available options when testing a 
particular hypothesis (4). A systematic examination of the sequence of events using a 
model with minimal environmental influences is therefore essential to determine the 
genetic contributions, which phenotypically resembles the disease in humans (21, 26). 
Studies already reveal that the genetic scaffolding of humans is shared with many 
other organisms (46). The completion of the Human Genome Project is an asset in that it 
provides a foundation for determining functional parts of genomes in order to improve the 
health of individuals (47). Once the gene or genes responsible for atherosclerosis in an 
animal model are identified, they can then be matched against the human genome to 
enhance the understanding of the multifactorial process involved in human atherosclerosis 
(26). The comparative analyses of genome sequences are of great value because common 
functions between two organisms are often conserved, and thus encoded within the DNA 
(47). 
The pigeon {Columba livia) originated from Europe, Asia and North Africa, giving 
rise to hundreds of varieties (48). The use of the pigeon as a model is exceptional because, 
both resistant breeds as well as susceptible breeds, which spontaneously develop 
atherosclerosis, exist (49). Clarkson as well as others have described the development of 
spontaneous atherosclerotic lesions in the White Carneau (WC) pigeon as nearly identical 
with those in humans, both grossly, microscopically, (8, 13, 14, 50, 51) and biochemically 
(52). 
Kjaernes reported that the results of atherosclerotic research in animal models often 
contradicts the effects found in humans, while the events in WC pigeons regarding lesion 
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properties and location are quite similar to those in humans (11). Kjaernes observed that the 
spontaneous lesions found in WC pigeons, develop primarily at sites of low sheer stress 
such as the celiac bifurcation of the aorta, which supports Caro's low sheer stress 
hypothesis (at sites of turbulent flow) (11). This same pattern was also observed in human 
autopsies (11, 49). It was therefore suggested that the pigeon may be the best model to 
study the development of atherosclerosis in humans (4, 11). 
The care and feeding of pigeons is such that they can be maintained in a wide 
variety of seasonal climates as long as water is kept from freezing and that they are 
permitted limited exercise in the form of a flypen (48). In general, a 12-hour light and 
dark cycle is recommended, although a 14-hour light cycle will enhance breeding (48). 
Pigeons achieve sexual maturity by 6-7 months and achieve peak breeding between 3-6 
years (48). 
Some of the advantages of using the pigeon as a model to study heart disease 
include; susceptibility to atherosclerosis, lesions that are similar to those in humans, based 
on location, histology, and progression, low cost, easy handling, sufficient size, and 
relatively long lifespan (4). Some disadvantages of using pigeons are that they are difficult 
to sex; they mate for life and often live well into their twenties. If separated from their 
partner, it can take up to a year before pigeons will select a new mate and reproduce at a 
maximum rate of two eggs every 6 weeks, from spring to early fall (15). Pigeons are 
nonmammalian (although both sexes produce a crop milk secretion to feed their young) 
(53); they are at risk of developing a herpes virus associated with atherosclerosis (50, 54); 
and they undergo many changes in lipoprotein metabolism during egg-laying and through 
the first few days after hatching (4). 
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In addition, all pigeons, unlike humans, lack apo-E, apo-B-48, and chylomicron 
formation (52). Because both breeds share the same commonalities of cholesterol transport 
explained later in this report, the lack of apo-E and apo-B48 cannot explain susceptibility in 
the WC and resistance in the SR, and therefore removes Apo-E and Apo-B-48 as risk 
factors for the development of atherosclerosis (13, 50). 
The pigeon has been the most widely used avian species in atherosclerotic research 
(8, 52). The primary site of plaque development in WC pigeons is at the celiac bifurcation 
(branch point) of the aorta (1, 52). As time progresses, lesions develop at other sites in the 
aorta and in the coronary arteries (50). Clarkson et al., first reported that WC pigeons 
develop spontaneous atherosclerosis while other breeds such as the Show Racer (SR) 
pigeons maintain resistance (49). The SR pigeons originated from racing homers about 
185 years ago and have remained a closed breeding colony for more than 45 years (52). 
Clarkson et al., suggested that atherosclerosis in the WC pigeon is the result of a genetic 
factor, independent of other risk factors (8, 13, 55). 
Morphological analysis of aortas in WC pigeons revealed that lesions are present in 
all WC pigeons with no difference between genders (8). The lesions appear as raised 
yellow plaques that project into the lumen and are mostly found at branch points (sites of 
bifurcation). Although some lesions do develop along the straight segments of the aorta, a 
few plaques practically occlude the lumen of the aorta (8). Most of the spontaneous lesions 
are primarily fibrous (8). The predictability of these spontaneous lesions at the celiac 
bifurcation of the aorta make the WC pigeon a good model system for the study of 
metabolic parameters associated with the disease (10). 
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Paired muscular intimal thickenings are present at the celiac bifurcation of 10-day 
embryos and very young birds, with cushions of SMCs protruding into the lumen (10). In 
squabs, ridge-like thickenings were observed prior to the presentation of lipid along the 
lateral edges of the celiac orifice (10). By 4-6 months, the earliest lipid accumulation can 
be seen on the surface of these intimal cushions (10). According to Santerre, aggregates of 
SMCs appear to be a prerequisite for lipid accumulation and appear to dominate 
metabolism in the healthy state, as well as in all lesions and at all stages of the spontaneous 
diseased state (10). Vacuoles appear to develop from the dilated granular endoplasmic 
reticulum in modified SMCs of very young WC pigeons (14). The appearance of 
thickened basement membrane envelopes on modified SMCs, disorganization of elastic 
laminae, and excess collagen in WC pigeons are strikingly similar to those features seen in 
the early lesions found in humans (14). 
Lesions that develop in WC pigeons increase in size with age, and progress through 
various stages of plaque development (49). The activation of cells involved in the disease 
process, relies not only on local effects, cytokines, and growth factors, but also on intrinsic 
genetic properties (49). Advanced lesions contain intra- and extracellular lipids, 
cholesterol clefts, fibrous tissue, SMCs, and what appears to be macrophage foam cells 
(52). Only after atherosclerotic lesions appear is there an increase in the influx of LDL at 
specific sites of arterial lesions (50). As lesions progress, ulcerations, hemorrhage, mineral 
deposition, and even bone formations are common (52). Complications of thrombosis and 
complete occlusion in the WC pigeon develop only during the later stages of the disease 
(8). A unique feature in WC pigeons, in contrast to other animal models is that myocardial 
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infarctions occur in older pigeons displaying the most severe stage of atherosclerosis (50). 
Richards (as well as Santerre) studied the spontaneous development of lesions in 
WC pigeons from 1 month to 3 years of age (and 1 month to 6 years respectively) to 
document their location and stages in development (10, 12). Richards observed that in 
hatchlings, lesions progressed as age increased, though the final distribution pattern was 
apparent by 5 months of age (56). In other words, no new lesions developed after this age 
(12). 
Comparing and contrasting susceptible and resistant breeds are useful to examine 
the biochemical functions involved in atherosclerosis (49). When comparing lipid content 
in the celiac bifurcation at 1 day, 6 weeks, 12 weeks and 6 months, Hajjar et al., found that 
total lipid content in the WC pigeon was significantly greater by 6 weeks of age and 6 
months of age when compared to the SR pigeon (57). A dramatic increase in non-esterified 
fatty acids (NEFA) was also observed by 6 weeks of age in the WC when compared to the 
SR and remained significantly greater as age increased. Also apparent was a marked 
increase in cholesterol at celiac sites by 6months in the WC pigeon as compared to the SR 
(57). 
In another study, Hajjar et al., found that by 6 months of age there was a dramatic 
decrease in the P/O ratios of ATP synthesis and oxygen consumption in the celiac cushions 
of the WC as compared to the SR (17). They suggested that the reduced ability of the WC 
to produce ATP was of a genetic origin (17). Work conducted by Curwen et al., on 
quantitative electrophoretic profiles of glycosaminoglycans (GAG) in WC and SR at 1 day, 
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6 weeks, 6 months and 3 years of age revealed that the WC contained more total 
glycosaminoglycans than the SR at all ages in the celiac bifurcation (16). After 
6 months, changes were noted in specific GAGs between WC and SR, suggesting GAGs 
play a role in the pathogenesis of atherosclerosis (16). 
While examining aortic tissue of both WC and SR Hajjar et al., did not notice any 
ultrastructural differences between the two breeds until 6 months of age (57). It was at that 
point that they consistently found more debris-like material in the celiac cushions of the 
WC when compared to the SR pigeon (57). Some of this extracellular membranous 
material appeared to be uniformly round while other vesicles were more heterogeneous in 
shape, but both appeared to originate from SMCs (57). 
Both SR and WC pigeons, unlike humans, maintain typical cholesterol levels of 
approximately 300 mg/dl. Approximately, two thirds of their cholesterol is transported in 
the form of HDL as part of their normal cholesterol pathway in contrast to humans, which 
are LDL carriers (45, 52, 58). Since most animals do not develop spontaneous arterial 
lesions, they have been historically placed on high-cholesterol diets for months at a time 
prior to examination of their arteries (11). Upon feeding a 0.5% cholesterol diet, both SR 
and WC pigeons develop marked hypercholesterolemia of approximately 1,000 to 2,000 
mg/dl (52). The marked increase in cholesterol concentrations interestingly causes the 
primary carriers of cholesterol to shift from HDL to B-VLDL and LDL. 
Apo-B becomes the predominant apolipoprotein in this induced state, and acyl-CoA-
cholesterol acyl transferase (ACAT) activity increases to facilitate transport, which is 
similar to humans and other animals (50). 
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Examination of WC pigeons to determine whether blood pressure (BP) plays a 
major role in the progression of atherosclerosis, showed no significant effect of season or 
age on BP between 6-12 months when early atherosclerosis begins; nor was there a major 
difference in BP between SR and WC (59). Wagner did find, however, that after 6 months 
on an atherosclerosis-inducing diet, BP increased as a result of atherosclerosis (59) making 
it therefore a secondary effect. 
While examining the lumen of the aorta, Wagner found that the WC pigeon has a 
larger lumen compared to the SR pigeon although there were no differences between wall 
thicknesses. He also found that the WC wall contained greater amounts of elastin but little 
difference in collagen (49). These differences were not found to occur in response to 
plaque development but were the result of intrinsic properties within the aorta attributable 
to each specific breed of pigeon (49). 
In addition, when spontaneously atherosclerotic WC pigeons are fed an 
atherogenic diet, lesion development is accelerated (1, 52). These induced lesions contain 
lipid engorged macrophage cells, that form fatty streaks, which differ from those that 
develop spontaneously (1, 50, 60). This diet-induced state not only exacerbates, but alters 
the progression of the spontaneous disease (1, 52, 61, 62), no longer making it a valid 
model to study the underlying early mechanisms of the disease (60). In addition, upon 
examination of the induced disease, locations of these lesions are typically found at sites of 
high physical stress, which correlates with Fry's high shear stress hypothesis, unlike lesions 
found in non-induced states (11, 49). Once the atherogenic diet is replaced by a typical 
non-inducing pigeon chow diet, cholesterol concentrations in both SR and WC pigeons 
return to normal levels within a few weeks (52). In the presence of an atherogenic diet, 
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resistance to atherosclerosis is maintained in the SR pigeons unlike the WC pigeons. This 
difference appears to be genetically controlled (55), and the absence of lesions in the SR 
pigeons suggests that genetic factors are responsible for resistance to atherosclerosis (8, 
15). 
Breeding experiments present the most convincing evidence regarding genetic 
influence on the development of specific atherogenic lesions (55). After crossbreeding Fl 
WC and SR to produce F2 progeny, Goodman and Nash suggested that genetic factors play 
a major role in atherosclerosis (9). They also reported that genetic factors for initiation 
were largely independent of those responsible for lesion progression (9). Smith et al., 
reported that a limitation of Goodman and Nash's study was that the pigeons were placed 
on a high cholesterol diet which altered and accelerated the spontaneous disease 
progression, and that the progeny were never backcrossed to determine the inheritance 
pattern (15). 
In 2001, after completing a 15-year study Smith, Smith and Taylor reported the 
mechanism of inheritance for susceptibility to spontaneous atherosclerosis in WC pigeons 
(15). They demonstrated this inheritance pattern through crossbreeding inbred strains of 
susceptible WC and resistant SR pigeons to produce Fl and F2 progeny and finally 
backcrossing the Fl progeny with parental WC and SR pigeons (15). Upon examination of 
lesions visible at the celiac bifurcation of the various progeny, they determined that 
atherosclerosis was inherited as a Mendelian single-gene, autosomal recessive pattern (15). 
Smith et al thus concluded that the WC pigeon is an effective model to study genetic 
factors that lead to the development of lesions at the level of the arterial wall (15). They 
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therefore determined that the genetic patterns of spontaneous lesion development in the 
WC pigeon makes it a simplest case scenario due to the absence of risk factors (15). 
To better understand genetic factors responsible for both susceptibility and 
resistance, Anderson compared differential gene expression between WC and SR pigeons 
(63). Her work on SMCs (from the celiac bifurcation) in-vitro (representing a compressed 
time- frame of approximately 2-3 years in-vivo) showed that genetic differences do in fact 
exist between both breeds. Anderson found for example, ribosomal biogenesis was clearly 
upregulated in the SR (63). While 7 genes were unique to the WC (27copies) only 1 gene 
(1 copy) was unique to the SR. Five genes were differentially upregulated in both the WC 
and the SR, yet the number of copies in the SR greatly exceeded those in the WC (81:10). 
The primary contributor of this regulation was Ribosomal Protein L3 (RPL3) that was 
differentially upregulated 69 times in the SR (63). Given the number of genes that were 
differentially upregulated between both breeds, the regulation in the SR was more than 
twice that of the WC. 
Anderson also reported a marked difference in energy metabolism between both 
breeds. While the genes Cyctochrome C oxidase subunit I (COI), NADH dehydrogenase 
subunit 4 (ND4), NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 (NDUFAIO), 
and ATP synthase subunit 4B (ATP4B) representing oxidative phosphorylation were 
upregulated in the SR, Enolase 1 (ENOl), Glucose 6 phosphate Isomerase (GPI), and 
Lactate Dehydrogenase (LDHA) which participate in glycolysis, were upregulated in the 
WC pigeon (63). Additional metabolic differences reported by Anderson revealed that 
genes expressed by the SR were indicative of a healthy smooth muscle contractile 
phenotype (63) while the susceptible WC pigeons expressed genes that represented a 
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synthetic phenotype (or loss in smooth muscle regulation). Anderson also found that the 
genes expressed by the resistant breed indicated that they were much better at organizing 
and maintaining the extracellular matrix while genes expressed in the susceptible WC 
indicated a lack of structural integrity of the matrix (63). Anderson concluded the 
differences in genetic expression patterns between both breeds helped to explain factors 
responsible for both susceptibility and resistance however, she was unable to discern the 
chronological sequence of events for initiation and progression of atherosclerosis (63). 
Based on the available research, it is reasonable to suggest that the WC pigeon is one of the 
best models to study the genetic effects at the level of the arterial wall that are associated 
with human atherosclerosis (4). 
Identification of Differentially Expressed Genes 
Expression patterns of genes are continuously changing during the growth and 
differentiation of tissues (19). The expression of a given gene in a cell at any one point in 
time defines the characteristics of the cell and impacts the downstream effects which can 
ultimately invoke a disease state (19). Given that atherosclerosis is a disease that develops 
slowly over time presenting various characteristics, it is important to choose a method or 
methods that will capture genetic material and effectively identify genes of interest, 
particularly those that are different between known ages of development. 
Research conducted on WC pigeons shows that in the aorta chemical changes occur 
by 6 weeks of age while morphological changes are observed by 6 months of age (2, 16, 
57, 64). Given these results, it is necessary to utilize a method that examines differences in 
genetic expression between these known ages of development. 
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Many methods are available to target differential expression between two similar 
systems. Some of the methods include Serial Analysis of Gene Expression (SAGE), 
Differential Display (DD), Subtractive Hybridization (SH), Microarray and 
Representational Difference Analysis (RDA). One of the main advantages of all of these 
methods except for Microarray is that they do not require prior knowledge of the sequences 
to be analyzed (65). Although Microarray can only analyze known genes it does allow for 
large numbers of genes to be compared in a single assay (66, 67). An advantage of both 
SAGE and DD is that both methods only require small amounts of total RNA as their 
starting material (19, 65, 68). A disadvantage is that primers are attached to the 3' end of 
transcripts in both SAGE and DD which may hinder their identification and 
characterization following Polymerase Chain Reaction (PCR) (69). 
Although DD is versatile, easy to monitor and offers ready access to sequence 
information (19, 70), a major disadvantage is the number of false positives when 
determining actual differences between transcripts (68-70). This is because determination 
of differential expression relies totally on "visual" examination of the bands from agarose 
gels (69). One study found that 19 out of 20 amplified bands that were analyzed were false 
positives (70). While SAGE amplifies thousands of sequence tags, because they are small, 
they offer little sequence information for novel genes (69). In addition the large numbers 
of transcripts that are generated make it cumbersome and rather time consuming to detect 
genes that are differentially expressed (69). 
The method of SH involves the removal of genes that are shared between two 
similar populations. Genes that do not hybridize with one another are therefore 
differentially expressed and remain single stranded (ss). Subsequent steps therefore require 
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additional methods such as the preparation of libraries to store the ss DNA which can be a 
cumbersome and costly process (19). 
Representational Difference Analysis is a positive enrichment technique that 
couples both SH and PCR to amplify only those genes that differ in their expression 
between two populations (69, 71, 72). The method of combining two populations includes 
the primer ligated target population known as the "testers" and the non-primer attached 
"drivers" which are greatly in excess of testers (69, 71, 72). Following the hybridization 
reaction, three types of populations result; driver:driver (non-amplified), testendriver 
populations that experience linear amplification, and finally the differentially expressed 
target populations known as, tester:tester that are exponentially amplified, diluting non-
differentiated genes beyond detection (69, 71, 72). Tyson and Shanahan successfully used 
this technique to compare differences between cDNA populations from human 
atherosclerotic plaques and normal segments of the aorta (69). 
One of the benefits associated with RDA include, its ability to detect transcripts of 
low copy number due to the combination of hybridization kinetics and exponential 
enrichment (71). This is especially important given that in a mammalian cell, 15,000 genes 
on average are expressed at any one time and of that approximately 83% of transcripts are 
present in only one copy per cell (71, 73). Also, only a small amount (100-250ug) of total 
RNA is needed (69) as the starting material. Unlike other methods, RDA produces longer 
expressed sequence tags (ESTs) (256bp on average) that are more likely to originate from 
their parent cDNAs (72) ultimately optimizing the number of positive outcomes. Another 
advantage of RDA is its ability to detect novel transcripts (72). In addition, RDA is cost 
effective, sensitive, relatively quick and yields a minimum number of false positives (< 
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5%), along with the fact that once the method is complete only differentially expressed 
genes remain (72). 
In light of the many advantages of RDA, some limitations remain. For example, 
differences between genes expressed at the moment that total RNA is extracted represent 
only a snapshot in time and therefore does not capture all the possible genes expressed in a 
cell. Because the method selects for expressed differences, it is possible that many of these 
genes have not yet been annotated, and results in genes being classified as "unknowns" 
(72). Low yield can result from poor techniques so it is essential to maintain meticulous 
care in planning as well as execution of techniques throughout the experiment to optimize 
recovery of material (71). In addition, any cDNA fragments that are less than 100-150 base 
pair in length are removed, which may potentially remove key genes of interest (72). An 
additional limitation can occur when an EST of interest lacks two sticky ends on the 5' 
prime ends of the double stranded cDNA. In this event, the tag is amplified linearly at best, 
and therefore washed out. The current use of a four-cutter enzyme in place of the 
previously used six-cutter optimizes the number of manageable sizes of cDNA that can be 
used with this technique. The subsequent use of an additional four-cutter can further 
optimize the recovery of genes of interest (72). Anderson's work included optimization of 
the RDA method that was provided by Pastorian et al., therefore reducing many of the 
limitations experienced with the method (63). When compared to other methods, RDA 
presents fewer limitations, making this an excellent method of choice. 
Work conducted by Anderson utilizing the optimized RDA method in WC and SR 
pigeon aortic cell cultures identified 165 genes that were differentially upregulated in 
SMCs (63). Seventy-four genes were differentially upregulated in the WC while 63 genes 
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were uniquely upregulated in the SR pigeon. While Anderson was able to identify many of 
the genes, because of the compressed developmental time-frame associated with her in-
vitro system, she was unable to determine their chronological sequence of expression 
associated with susceptibility or resistance. Anderson's findings emphasize the need to 
conduct future in-vivo experiments that compare selected ages, in order to reveal the 
chronological sequence of differential gene expression. Once the metabolic roles of the 
differentially expressed genes are understood, the sequence of events in the disease process 
can perhaps be elucidated. 
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Research Objective 
To distinguish between genes that are responsible for initiation of spontaneous 
atherosclerosis in the pigeon model and those responsible for progression by identifying 
genes that are differentially expressed at the celiac bifurcation of the aorta between 1 day, 6 
weeks, and 6 months of age in White Carneau (WC) pigeons. 
Genes that are differentially expressed early (1 day) will be considered to be involved in 
initiation of the disease while those that are differentially expressed later (6 weeks and 6 
months) will be considered to be involved in the progression of the disease. 
Hypothesis 
Genes responsible for initiation and progression of atherosclerosis in the WC pigeon will 
be differentially expressed at 1 day, 6 weeks and 6 months of age. 
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Experimental Design 
1. Representational Difference Analysis (RDA) will be conducted to compare genes 
differentially expressed in-vivo at the celiac bifurcation of the aorta in atherosclerosis 
susceptible WC pigeons. 
2. Vertical comparisons between three age groups (outlined in Figure 1) will be performed 
using RDA in order to examine differently expressed genes: 
comparison 1 (C-l):l day versus 6 weeks, comparison 2 (C-2): 1 day versus 6 months, and 
finally comparison 3 (C-3): 6 weeks and 6 months. 




METHODS AND MATERIALS 
Pigeon Colonies 
The WC pigeons were obtained from University of New Hampshire (UNH) 
colonies that were housed in fly coops at ambient temperature and allowed free access to 
water, Purina Pigeon Chow Checkers, and Kaytee Red Grit. The origin of the WC 
population began from four pairs of birds that were purchased in 1915. They were then 
mated with a few outsiders and a few more additions to complete the entire inbred WC 
population by 1916 at the Palmetto PigeonTlant in Sumter, South Carolina (8). The UNH 
colony was established in 1962 from WC pigeons obtained from the Palmetto Pigeon Plant 
and have remained inbred since that time (63). The WC pigeons that are housed in the 
UNH colonies are maintained under the guidelines of the UNH Animal Care and Use 
Committee (Approval # 050601). 
Whole Tissue Extraction Followed by cDNA Synthesis from Total RNA 
Previous to this current research project RNA was extracted from aortic tissue at the 
celiac bifurcation of WC pigeons at 1 day (experiment #137), 6 weeks (experiment #190a-
2), and 6 months of age (experiment #162) by Anderson in this lab. Surgical collection of 
the celiac bifurcation of six WC pigeons at 1 day of age was conducted on two separate 
occasions and stored in KNAlater® Solution (Applied Biosystems), (a tissue collection 
RNA isolation stabilization solution), according to the standard protocol provided with this 
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product (74). Once 62mg of whole tissue was collected, the tissue was frozen in liquid 
nitrogen and ground by mortar and pestle, which was then combined with 1ml of Quantum 
Prep® Master Blaster (BioRad) an RNA extraction reagent, according to the standard 
protocol provided with the product (75). Master Blaster separates RNA from DNA and 
cellular debris resulting in the collection of total RNA (experiment #137). 
At 6 weeks of age, the celiac bifurcation of two female and one male WC pigeons 
was surgically removed using the same protocol as described for the WC pigeons at 1 day 
of age except, KNAlater® was not used. The reason for this was simply due to the fact 
that tissue at 6 weeks of age is larger, making tissue collection easier. This allowed for the 
celiac bifurcation of the birds to be collected on the same day and was followed 
immediately by RNA extraction using TRIzol® (Invitrogen) instead of Master Blaster, 
according to the standard protocol provided with Trizol® (76). The result was the 
successful collection of total RNA (experiment #190a-2). At 6 months of age, the celiac 
bifurcation was surgically removed from 3 males and 2 females according to the same 
procedures outlined at 6 weeks of age resulting in sufficient amounts of total RNA 
(experiment #162). 
Complementary DNA synthesized from total RNA of 2 similar populations, is the 
starting material for RDA (69, 71). Once 1 ug of total RNA was prepared at each age as 
previously laid out the process of synthesizing cDNA ensued (63). The BD SMART ™ 
PCR cDNA Synthesis Kit (BD Biosciences Clontech Division #K1052-1), which includes 
special oligo dT primers, was used to synthesize single stranded (ss) DNA from mature 
mRNA with Poly-A tails by reverse transcriptase. This was followed by second strand 
synthesis of DNA to yield full length double stranded (ds) cDNA. An advantage of the 
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SMART program is that as little as 50ng of total RNA are needed to select for mRNA in 
order to produce and amplify cDNA in sufficient amounts for RDA (63). Finally, the ds 
cDNA was placed in a -80° C freezer for storage awaiting the following RDA experiments. 
Quantitative Analysis. Matching and Size Distribution of cDNA 
Eighteen samples of cDNA (6 samples from each age 1 day, 6 weeks, and 6 
months) were transferred from the -80° C freezer to the -20° C freezer for short-term use. 
Standard aliquots of 2ul from each sample of cDNA in a total volume of 70ul Tris-EDTA 
(TE) buffer (pH 8.0) were quantitated using spectrophotometry at 260nm (A260) to 
determine yield. Next, 0.7ug of cDNA from each sample was run on a 1.2% surface 
tension gel with lOul ethidium bromide (O.Olmg/ml) at 85 volts for 30 minutes. A 
photograph of the cDNA samples under UV light using the MultiDoc-It Digital Imaging 
System (UVP Model M-20) revealed a poor pattern of fluorescing as most of the lanes 
appeared blank. Each of the cDNA samples should appear at this stage as a smear ( as 
opposed to distinct banding patterns) that range between 300 and 7000 base pairs (bp) with 
the greatest intensity between 2000 to 3000 base pairs to be considered for RDA (63, 72). 
It was then decided to rerun the samples using a slightly thinner gel and to increase the 
ethidium bromide to 15ul to ensure fluorescing of any cDNA smears that are present. In 
addition, the volume was set at lul therefore increasing the amount of the cDNA in each 
sample from 0.7ug to at least l.Oug. These changes resulted in quality smears in 88% of 
the cDNA samples. Precise matching of cDNA smears according to bp size distributions is 
essential to ensure that differentially expressed products are reflective of two similar 
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comparisons (72). The three selected ages were visually matched, and stored at -20° C to 
await RDA. 
Representational Difference Analysis (RDA) 
As described previously in the Literature Review, RDA is a multistep enrichment 
technique that couples SH with PCR to discriminately select and amplify only transcripts 
that are differentially expressed between two populations of cDNA. The RDA protocol, 
provided by Pastorian et al., (72) was systematically modified in this laboratory by 
Anderson (63) to minimize sample losses during multiple chemical and physical 
manipulations. 
A. Amplicon Preparation of cDNA by Restriction Digest 
Five micrograms from previously matched 1 day and 6 week WC pigeon cDNA 
samples (comparison one), were each combined with 4.44ul DpnII enzyme (lOU/ul; New 
England BioLabs R05431), lOul 10X DpnII buffer and 18.2 Mohm water (in a total volume 
of lOOul), and digested in the MasterCyler Gradient Thermal Cycler (TC) (77) (Eppendorf 
#5331; 115V), for 18 hours at 37° C. DpnII is a four-cutter enzyme that recognizes and 
cuts at the 5 prime end of the GATC site of double stranded cDNA leaving "sticky" ends 
that allow for ligation of primers and amplification during subsequent steps. In addition, 
DpnII cuts the cDNA into amplicons that are on average 256bp, (ranging in length from 
200 to lOOObp) making them manageable in length which ensures amplification by PCR 
(69, 72). 
Following digestion, both samples were transferred to Phase Lock Gel tubes (PLG) 
(Eppendorf # 955154151) and extracted first with lOOul of phenol-chloroform-isoamyl 
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alcohol (PCI) and centrifuged (Eppendorf Model #5415D) at 14,000xg for 5 minutes 
followed by the addition of lOOul of chloroform and repeated centrifugation. The 
advantage of the PLGs is that they separate proteins and organics from the aqueous cDNA 
phase and optimize recovery of cDNA. 
The recovered lOOul aqueous cDNA was run through Micro-spin S-300 HR Spin 
columns from Sephacryl® and centrifuged at 735xg for two minutes to remove small 
pieces of cDNA less than 100-150bp in length and any remaining restriction reagents. The 
samples were incubated overnight at -20° C in a mixture of lul glycogen (20 mg/ml), 0.1 
volume (lOul) 3M sodium acetate (pH 5.3) and 2.5 volumes (250ul) of 100% molecular 
grade ethanol to precipitate the cDNA out of solution further purifying the pellets. 
The following day both tubes were centrifuged at 16,000xg for 18 minutes to pellet 
the cDNA. Each pellet was washed with lOOul of 70% ethanol for an additional 2 minutes 
to precipitate the glycogen and salt, purifying the cDNA. The supernatant was carefully, 
vacuumed off from the cDNA using a lOul pipette tip to help prevent loss of the pellet. 
The rim of the tubes were wicked dry with a paper towel and laid on their side to air dry. 
Drying each cDNA pellet as much as possible facilitates the resuspension of cDNA in 20ul 
of IX TE buffer. Resuspended cDNA was stored at -20° C for no more than 2 days or was 
used immediately in the ligation of primers. 
B. Preparation of Primers for Ligation to Drivers 
The 12 and 24 primer sets presented in Table 3 purchased from Genosys (a 
subdivision of Sigma), were recommended by Pastorian (72) and successfully used by 
Anderson (63). The non-complementary interchangeable primer sets allow for ligation of 
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primers to targeted cDNA populations, which prevent the unintentional amplification of 
cDNA populations from previous rounds of RDA. This results in specific amplification of 
true difference products. 
Table 3: 12 / 24 RDA Primer Sets 
Primer Set 
A Driver 
B Tester Round 1 
C Tester Round 2 
D Tester Round 3 
E Tester Round 4 
















To prevent the hydrolysis of lyophilized primers from frequent thawing and 
refreezing throughout RDA, each of the (12mers and 24mers) primers were dissolved in 
specified amounts of IX TE buffer according to the molecular weight (MW) provided by 
Genosys. The absorbance (A260) of each of the primers was determined and calculated 
with the manufactures MW, along with the dilution factor to determine the actual 
molecular weight of each primer dissolved in IX TE buffer. Two different sets of aliquots 
were then prepared in single use tubes, one set for the A primers and another set for primer 
sets B-F and are as follows. Primer set A included: 12/24Amers (4.5ug and 9.0ug) and 
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24Amers (25ug). Each of the primer sets B-F included aliquots of 12/24 primers (4.5ug 
and 9.0ug), 24 primers (4.5ug) and 24 primers (18ug) that were stored at -20° C, ready for 
use. Primer sets A 12/24mers were used to prepare drivers for each of the three 
comparisons. Primer sets B through D 12/24mers were used to prepare testers for each of 
the 3 rounds in each of the three comparisons to prevent unintentional amplification from 
previous rounds throughout the RDA experiments. Primer sets E and F were not used 
during the following steps however, were prepared in the event that additional rounds were 
conducted, or as alternate primers during the preparation of drivers or testers. 
C. Ligation of Primers to Drivers 
Thel2/24mer primer set A mix (4.5 ug/9.0ug) was removed from the -20° C 
freezer, thawed, pulse spun, and kept on ice. An aliquot of 9ul of 10X ligation buffer (New 
England Biolabs) was thawed (kept on ice) and added directly to the 12/24mer mix 
followed by enough Mohm water to bring the total volume of this core mix up to 45ul. 
Both cDNA samples were removed from the -20° C freezer and thawed, and the total 
contents (20ul) were transferred to thin-walled 0.5ml PCR tubes. Twenty microliters of the 
core mix was then added to the PCR tubes containing the cDNA to bring the total volume 
to 40ul. The PCR tubes were placed in the preheated TC at 55 ° C, preset to the "Slow 
Cool" program, designed and optimized by Anderson (63). The program runs for 
approximately 40 minutes and holds at 8° C until samples are removed. During this step, 
the 12mers form temporary bridges with the 3 prime blunt ends of ds cDNA while the 
GATC site on the 12mer anneals with the CTAG overhang on the 5'end of cDNA forming 
hydrogen bonds. This allows the 24mers to temporarily anneal with nucleotides of the 
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12mer and hold them in place in preparation for ligation of the 24mers to the GATC sticky 
ends of the cDNA in the next phase. 
A core mix containing 1 lul 10X ligation buffer, 90ul Mohm water, and 9ul T4 
DNA ligase enzyme (New England Biolabs # M0202S) was made. Fifty microliters of this 
mixture was transferred directly into the PCR tubes that contained the cDNA mixture, and 
was incubated at 15° C overnight. During this step, the 24mer is ligated to the CTAG 5' 
sticky end of the cDNA forming a covalent bond that was previously restricted by DpnII. 
Following the ligation step, the cDNA products were incubated at 65° C for 10 minutes to 
deactivate the ligase. Since the 12mers are not phosphorylated they easily dissociate from 
the 3' end of the cDNA when incubated at 65° C (18). 
The cDNA samples were run through S-300 spin columns as previously described 
to remove ligase, buffer, 12mers, and any tags less than 100-150bp in length. The 
recovered volume of the eluate primer-ligated cDNA products was increased by lOul of 
Mohm water and the lOOul total volume was placed on ice. 
D. PCR Amplification of Drivers 
A core mix of 250ul 10X PCR buffer, 400ul 25mM MgCl2, 62.5ul lOmM dNTPs 
and 1487.5ul Mohm water was prepared. Of that, 240ul was transferred into another tube 
and placed on ice to use with Taq DNA Polymerase (5U/ul Promega Corporation Ml865). 
To the remaining core mix, 15ul of the same 24mer set-A (25ug) used to ligate primers 
onto drivers was added with 85ul of Mohm water to bring the total volume to 2060ul. The 
core mix was divided equally between the two ligated cDNA populations and then 180ul 
was transferred to 6 new PCR tubes for each population. The 12 PCR tubes were placed in 
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the preheated TC at 72° C, and incubated for 1-2 minutes to fully extend the cDNAs, and to 
create primer-binding sites on the 3' ends. Thirteen microliters of Taq polymerase was 
added to the 240ul of core mix sitting on ice, and 20ul was added to each of the 12 PCR 
tubes incubating in the TC. The PCR driver program was run for an additional 5 minutes at 
72° C to fully extend the double stranded 24mer cDNA amplicons followed by 25 cycles 
that alternated between denaturing at 95° C for 45 seconds, followed by 4 minutes at 72° C 
to amplify the cDNA. A final incubation at 72° C for an additional 10 minutes ensured 
extension of the cDNA drivers. The populations were pooled, extracted with PCI and 
chloroform, precipitated, washed, vacuumed as previously described, and then resuspended 
in lOOul of TE buffer. 
E. Removal of Driver PCR Primers by DpnII 
After the completion of amplified drivers, a restriction digest comprised of 90ul of 
cDNA driver, 10.5ul of 10X DpnII buffer and 4.5ul DpnII enzyme was incubated overnight 
at 37° C to remove the primers, regenerating the 5' sticky ends. Both cDNA populations 
were phase extracted with PCI and chloroform, purified with S-300 spin columns, followed 
by an overnight precipitation, ethanol wash, vacuuming, and finally resuspended in 50ul of 
IX TE buffer. 
The yield of amplified restricted drivers was determined by measuring absorbance 
at A260 using an aliquot of 1.5ul of cDNA in a total volume of 70ul TE buffer. Aliquots 
(0.5ug) of restricted cDNA drivers and unrestricted drivers were run on a 2.0% agarose gel 
at 75V for 60 minutes, stained with 5ul ethidium bromide (O.Olmg/ml), and photographed 
under UV light. Size distributions of the driver amplicons should appear as a smear as 
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opposed to distinct bands, ranging between 150-lOOObp (72). While bands are not usually 
visible until follow up rounds, which reflects the removal of cDNA lengths common 
between both populations, visual analysis revealed that distinct bands were present in all of 
the driver populations. The banding patterns ranged mostly between 250-750 bp with the 
brightest intensity around 500 bp (well within the recommendations), therefore verifying 
successful amplification and restriction of drivers and an abundance of differentially 
expressed transcripts. Visual comparison between primer-ligated cDNA and restricted 
cDNA revealed successful restriction digest by DpnII. Drivers were frozen at -20° C until 
the following step. 
F. Preparation of Testers 
Each of the driver products were used to create the tester population of round one. 
The ligation procedure is primarily the same as that performed for drivers except, that a 
new interchangeable set of primers was used in each successive round of RDA to prevent 
the unintentional amplification of transcripts from previous rounds. One microgram of 
driver, along with a new set of B 12/24mers, was used to perform ligation in a total volume 
of 60ul using the "Slow Cool" program. Following overnight enzymatic ligation at 15° C, 
the TC was heated to 65° C for 10 minutes to deactivate the ligase. The newly ligated 
cDNA products served as the testers in the subsequent steps of subtractive hybridization. 
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G. Subtractive Hybridization of Species Common to both cDNA Populations 
In each round of SH, the amount of driver used remained constant (5.0ug). The 
amount of tester on the other hand was reduced in each consecutive round (1:10, 1:100 and 
1:5000) to ensure that only differentially upregulated products between the comparisons 
will result (72). Thirty microliters (0.5ug) from the newly ligated tester populations was 
transferred into new tubes. Five micrograms from each driver was then added to the tester 
populations. The total volume in each tube was adjusted to lOOul by adding IX TE buffer 
resulting in two reciprocal SH reactions. Both tester:driver populations (C-1, lDay:6weeks 
and 6weeks:lDay) were then extracted with PCI and chloroform, precipitated for a 
minimum of 4 hours or overnight at -20° C, washed, vacuumed, and resuspended in 4ul of 
hybridization buffer which helps to facilitate the hybridization reaction of like proteins 
(72). 
One microliter of 5M sodium chloride (NaCl) was added to two new PCR tubes, 
and then placed in the TC. Both of the resuspended (4ul) testendriver populations were 
placed in the TC at 95° C, with the PCR tubes containing NaCl for one minute, to denature 
the double stranded cDNA of the tester and driver populations and heat the NaCl. The 
contents (4ul) of the tester:driver populations were quickly transferred into the tubes 
containing NaCl (facilitates hybridization reaction), followed by the addition of 20ul of 
mineral oil to prevent dehydration and loss of material. Both of the PCR tubes were 
returned to the TC and incubated at 95°C for an additional 3 minutes, to ensure that all the 
cDNA species were denatured. The TC was reset to 67° C and hybridization was allowed 
to proceed for 24 hours followed by the addition of 45ul of Mohm water to each of the 
completed hybridization reactions. Both tubes were placed in the -20° C freezer for 
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storage, or an aliquot of lOul from each SH population was transferred into 2 new PCR 
tubes to be used for amplification. 
H. PCR Amplification of Round One Subtractive Hybridization Products 
Amplification of the SH products results in three possible outcomes. The first 
experiences no amplification because hybridized driver:driver populations lack primers on 
both of their 5'ends. The second products, testerrdriver ideally have primers ligated to the 
5' end of the tester and therefore experience linear amplification at best. Finally the target 
population, tester:tester contains primers on both the 5' ends of hybridized cDNA which 
are amplified exponentially. Although drivers are much in excess of testers, the absence of 
primers and the exponential amplification of targeted testers cause the drivers to become 
diluted beyond detection due to such low copy number. 
A dilution step added during the extension step of the 7th cycle of PCR at 72° C 
effectively replaced the use of mung bean nuclease (72) ensuring that any linearly 
amplified single stranded cDNA populations were reduced below the point of detection. 
This was carried out by the addition of 4 new PCR tubes for each tester:driver population 
which contained 180ul of core mix and included the same B 24mers that were used during 
the ligation step along with the addition of 20ul Taq mix. Finally, aliquots of lOul were 
transferred from the tester:driver populations already in the TC to each of the newly added 
PCR tubes for a total volume of 210ul. The TC was resumed for an additional 20 cycles to 
ensure that only exponentially amplifiable differentially upregulated products would be 
present. Following PCR, the products were pooled, extracted with PCI and chloroform, 
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precipitated, washed, vacuumed, and resuspended in TE buffer to yield lOOul, that were 
labeled as Round One Difference Products (DPI). 
I. Removal of PCR Primers by DpnII 
Eighty-seven microliters of amplified DPI was transferred into new tubes. Ten 
microliters of 10X DpnII buffer and 3ul DpnII enzyme were added for a total volume of 
lOOul in each tube. The tubes were incubated overnight at 37° C to restrict the 24Bmers 
from the tester populations and regenerate 5' sticky ends. The next day the round one, 
difference products were extracted, purified, precipitated, washed, vacuumed and 
resuspended in a total volume of 50ul IX TE buffer. 
Both difference products were quantified by measuring absorbance at 260nm using 
5ul from each DPI in a total volume of 500ul IX TE buffer. Calculations revealed the 
amount of cDNA ranged between 30-45ug for each of the rounds throughout the 3 
comparisons, which was well above the recommended 10-20 ug as suggested by Pastorian 
(63, 72). Five micrograms from the DPI products were separated on a 2% gel at 75V for 
60 minutes, and stained with 5ul ethidium bromide (O.Olmg/ml) to assess size distribution 
patterns. Although bands are not expected until the second or third rounds of RDA (72) 
visual analysis revealed distinct bands (Figure 2) ranging between 250 and 750 bp, well 
within the recommended 150-1000 bp. This was the case in all rounds of the three 
comparisons. 
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Figure 2: Round One Difference Products (DPI) 1 Day and 6 Weeks 
1 day (digested), lday lOkb 6 weeks (digested), 6 weeks 
J. Rounds Two and Three of RDA 
In each successive round of RDA, the amplified differentially upregulated products 
from the previous round of SH served as the tester for the next round. For example, the 
amplified difference products from round one (DPI) became the tester for round two, and 
the products from round two became the tester for round three. In rounds two and three the 
procedure used for the ligation of primers onto the 5'end of testers for SH and 
amplification of difference products was the same as for round one except in round 2, 
12/24mer C primers were used, and for round 3, 12/24mer D primers were used. In each 
round of SH, the amount of driver (5.0ug) remained constant, while the amount of tester 
was decreased from 0.5ug in round one, to .05ug in round two, to .OOlug in round three. 
During round two of PCR, the samples were subjected to the same number of cycles as in 
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round one; however, in round three, during the second half of PCR, the number of cycles 
was increased from 20 cycles to 25 cycles. Following PCR, the amplified hybridized 
testers went through the same restriction and purification steps as in previous rounds. 
Determination of yield and gel analysis also followed the same steps as in the previous 
rounds. The yield for each round was well within the recommendations as was the size 
distribution patterns of each of the gels. 
Storage of digested cDNA for more than two weeks can result in the ligation of 
sticky ends to one another (63). Frequent digests can result in the loss of cDNA yield. 
Therefore, since the round three products (DP3) were to be cloned simultaneously, DpnII 
digestion of the DP3 products from all three comparisons were conducted together just 
before cloning. 
Cloning of Subtracted Round Three Difference Products 
The pBluescript II SK+ (pBS) Vector (Stratagene #212205) was selected due to its 
easy ligation of cDNA inserts at the BamHI site (63). A restriction digest using BamHI 
enzyme (lOU/ul, Fermentas), as well as dephosphorylation with calf intestine alkaline 
phosphatase enzyme (CIAP, Stratagene #600015), was necessary to prepare the vector for 
the cDNA inserts. Five microliters of the pBS vector, 5ul 10X BamHI buffer, and 5ul 
BamHI enzyme (lOU/ul) in a total volume of 50ul was digested at 37° C for 1 hour. This 
step was followed by dephosphorylation with 30ul CIAP enzyme, and lOul 10X CIAP 
buffer in a total volume of lOOul that was incubated in the TC for 30 minutes at 37° C and 
then adjusted to 68° C for an additional 15 minutes. The CIAP catalyzes the removal of 
phosphates from the 5' end of cDNA, which prevents re-ligation to the 3' end (78). This 
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mixture was extracted with lOOul PCI and chloroform, precipitated, purified with S-300 
spin columns, washed, and vacuumed as explained in previous methods. The pBS vector 
was resuspended in 5ul of IX TE buffer, and stored at -20° C until its use. One microliter 
of pBS vector in a total volume of 50ul IX TE buffer was used to determine yield at A260 
followed by running 0.3ug of vector on a 1.2% gel with 6ul ethidium bromide at 85 V for 
25 minutes. The gel revealed a successful dephosphorylated linearized pBS Vector that 
appeared as a single band located at 3KB. 
The final digestion of the DP3 products from the three comparisons was then 
carried out using 3ul of DpnII enzyme in a total volume of lOOul in the same manner as in 
previous ligations. Digested DP3 products were followed up with extraction using PCI 
and chloroform, precipitation, purification, wash, and vacuum of populations followed by, 
the resuspension of each DP3 product in 50ul IX TE buffer. Five microliters of each DP3 
in a total volume of 500ul TE buffer was used to determine yield at A260. Aliquots of 
0.5ug of cDNA from each sample were run on a 1.2% gel at 75V for 60 minutes, and 
stained with 5ul ethidium bromide (O.Olmg/ml) as previously described. Results in Figure 
3 revealed distinct banding patterns and appropriate size distributions to proceed forward 
with the method. 
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Figure 3: Round Three DpnII Digestion of All Three Comparisons 
1 day:6 weeks Wkb 1 day:6 months Wkb 6 weeks:6 months lOkb 
Stratagene recommended that the concentrations of vector and inserts should be 
O.lug/ul (78). These concentrations were determined by Anderson to work best when in a 
ratio of 1:2 (insert: vector) during the ligation reaction (63). Rather than dilute the whole 
cDNA DP3 population and risk degradation, 2ul was aliquoted from the total volume (63). 
This aliquot was then diluted to the recommended concentration of O.lug/ul of which 0.5ul 
was then combined with l.Oul of vector, 0.5ul T4 DNA ligase, and l.Oul T4 buffer in a 
lOul total volume that was incubated at 4° C overnight. 
An LB/agar bacterial growth broth comprised of lOg NaCl, lOg Tryptone, and 5g 
Yeast, in a total volume of 1 liter of Mohm water at a pH of 7.0 was then mixed with 15g 
Agar and autoclaved. The broth was cooled to 55° C followed by the addition of 8ml X-
gal (lOmg/ml, Promega), 0.5ml IPTG (lOOmM, Promega), 1.0ml ampicillin (50mg/ml) and 
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2.5ml tetracycline (5mg/ml). This was poured into plates and allowed to set overnight at 
room temperature according to the XLl-Blue MRP' Supercompetent Cells protocol (79). 
The following day the pBS vector-ligated difference products were transformed into 
the XLl-Blue MRP' Supercompetent Cells (XL1-cells). A vial of SOC Medium (is a 
nutrient rich medium that improves transformation efficiency) was transferred from -20° C 
to a 42° C water bath to slowly thaw the SOC. Six 14ml tubes were chilled on ice while 
the XL1-cells were removed from -80° C and were slowly thawed on ice. Once thawed, 
lOOul of the XLl-cells were transferred into each of the 14ml tubes, followed by 1.7ul B-
Mercaptoethanol (serving as a reducing agent to cleave disulfide bonds). The contents 
were stirred gently every 2 minutes for 10 minutes (while on ice) so not to damage the 
cells. Next 2ul of pBS vector-ligated cDNA was transferred into the respective 
transformation tubes, which were stirred and incubated for an additional 30 minutes. All 
six transformation tubes were placed in a rack and heat pulsed in a 42° C water bath for 
precisely 45 seconds. Next, 900ul of the pre-warmed (42° C) SOC was transferred into 
each of the six 14ml transformation tubes, which were then shaken, at 230 rpm for 1 hour 
at 37° C to allow the cells to produce approximately one generation. Next, the Agar treated 
growth plates were warmed at 37° C and labeled to include 5 plates for each 
transformation, with one serving as a titer plate. Five microfuge tubes for each 
corresponding transformation reaction were labeled, and 2ul of transformation mixture was 
added to the 6 tubes that were labeled as titer tubes, while 40ul was added to the rest of the 
tubes (4 for each transformation). Next, 198ul of SOC was added to the 6 allocated titer 
tubes, while 160ul was added to the rest of the tubes for a total of 200ul in each tube. 
Finally, 200ul from the tubes were plated onto their respective plates, and allowed to soak 
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in for 15-20 minutes. The plates were then inverted, and incubated at 37° C to allow the 
colonies to multiply exponentially, overnight. Refrigeration of the plates followed to 
enhance the blue/white selection of the clones. 
Colonies of pBS vectors containing inserts will remain white because the inserts 
disrupt the coding region on the lacZ gene fragment of the vector, and those without inserts 
will produce blue colonies (78). The lacIqZAM15 lac gene is carried on the F' episome 
region of the XL 1-Blue MRF' Supercompetent Cells and allows for this blue/white 
selection (78). Ampicillin together with tetracycline, further selects for colonies that 
contain both the pBS Vector and F' episome respectively to help reduce the incidence of 
false positives (78). The use of tetracycline was reported by Anderson to reduce the 
incidence of false positives after she experienced a large number of false positives 
following the hand selection of (white) clones, only to find they contained no inserts (63). 
A total of 2304 clones were picked by hand (768 for each comparison) using sterile 
toothpicks and placed one in each of the 96-deep well plates containing 400ul Ampicillin-
2XYT media. These were sealed with Air Pore tape (Rainin) to allow respiration of the 
clones, while shaken at 180rpm for 17-18 hours and incubated at 37° C. The next day, 
140ul of 60% glycerol was added to each well, and the plates were then sealed, wrapped 
and placed in the -80° C freezer to await Rolling Circle Amplification (RCA). 
Positive and negative controls were conducted using the XL 1-cells and pUC18 
control plasmids supplied by Stratagene to evaluate the blue white selection of the XL1-
cells and to ensure their quality. Since the pUCl 8 plasmid does not contain inserts, the 
colony forming units (cfu), should remain blue for the positive control. This was the case, 
with too many cfu present to count (Table 4). As anticipated, the negative control resulted 
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in no cfu since pUCl 8 vector was not added to the XLl-cells. Titer plates (presented in 
Table 4) were also conducted to estimate the number of cfu for blue (pBS-no cDNA) and 
white (pBS-cDNA) inserts, and for the potential number of inserts in each transformation 
reaction. The controls correlated well with the outcomes described by Stratagene. 
Table: 4: Controls for Blue White Selection of XLl-Cells, pBS Vector & Inserts 
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The results for the titer plates in Table 4, revealed that on average, 93% of XLl-
cells contained pBS-cDNA inserts. These findings allowed proceeding to the next step of 
purifying and amplifying the cDNA inserts by Rolling Circle Amplification (RCA). 
Rolling Circle Amplification (RCA) of Bacterial Cultures 
The RCA Tempi Phi 500 Amp kit (Amersham Biosciences, #25-640-50) was 
selected to prepare the cDNA inserts for sequencing by releasing them from the XLl-cells 
followed by amplification. The protocol was adjusted by Anderson to use half the amount 
of the recommended reactants while providing the same results, and doubling the number 
of reactions that could be conducted with a single kit (63). The following procedures were 
the same throughout for each of the 24, 96-well plates. A cloned 96-deep well plate was 
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removed from -80° C and slowly thawed at room temperature for two hours or overnight at 
4°C. 
With a multi-channel pipetter, 2.5ul of Sample Buffer (5X 0.5ml) and 0.8ul of the 
cloned XL 1-cells were added to each well of a new shallow 96-well plate. The plate was 
sealed with strip caps, and pulse spun in a plate spinning head in the Beckman/Coulter 
Allegra 25R centrifuge, for 25 seconds at 5700 rpm and then placed in the preheated TC at 
95° C for precisely 3 minutes to lyse the XL1-cells and release plasmid vector-cDNA 
inserts from the cells, without denaturing DNA. The plate was removed and immediately 
placed on ice while preparing a master mix of 250ul Reaction Buffer (5X 0.5ml) and lOul 
Enzyme Mix (5X 20ul). An aliquot of 2.5ul from the master mix was then added to each 
well of the cooled plate bringing the total volume to 5.8ul. The plate was again sealed with 
the strip caps, and pulse spun for 25 seconds and placed in the preheated TC at 30° C for 16 
hours. The temperature was adjusted to 65° C for 10 minutes to denature the enzyme, and 
was then adjusted to 4° C until removal of the plate from the TC. The plate was then pulse 
spun for 25 seconds to collect the contents. Ten microliters of Mohm water were added to 
each well bringing the total volume to 15.8ul, and the plate was pulse spun again. 
The following restriction digestion reaction was conducted to determine whether 
the vector was in fact released from the XL 1-cells, and to assess whether the pBS vector 
contained an insert. The TC was preheated at 37° C while a master mix of 1 lul Bovine 
Serum Albumin (BSA) (lOmg/ml), 1 lOul 10X Multi Core Buffer, 329ul Mohm water, 50ul 
Hind III enzyme (lOU/ul), and 50ul Xbal enzyme (12U/ul) were added to equal a total 
volume of 550ul. The Hind III and Xbal are six cutter enzymes that recognize and cut 24 
bp upstream and 8 bp downstream from the BamHI site respectively. Using a new shallow 
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96-well plate, 5ul of the master mix was pipetted into each well with the multi-channel 
pipetter. Strip caps were removed from the RCA plate and 5ul from the total volume of 
15.8ul was transferred from each RCA well into the respective wells of the new plate 
containing the master mix. Strip caps were used to seal the wells, and the plate was pulse 
spun for 25 seconds and then placed in the preheated TC at 37° C for 2 hours. 
The digestion plate was removed from the TC after 2 hours and pulse spun to 
collect the contents. The strip caps were removed to pipette 4ul of gel loading dye into 
each well for a total volume of 14ul. The wells were again covered and pulse spun. Using 
the multichannel pipetter, 7ul aliquots were transferred row by row from the 96 digested 
samples, and were run on a 1.2% gel, with 7.5ul of ethidium bromide in a large 
electrophoresis gel bed at 85V for 30 minutes. The gel was photographed under UV light 
as previously explained to assess the location of XL1 -cells, pBS Vector and the digested 
cDNA inserts. Acceptable gels revealed three main components. The XL1-cells were 
located at the wells, while the pBS Vector formed a distinct band at 3000bp. A third band, 
the cDNA inserts, was located below lOOObp. To proceed, at least 88 of the 96 pBS 
Vectors had to contain cDNA inserts visualized on the gel below lOOObp before the entire 
plate could be submitted for sequencing (63). 
A new 96-well shallow plate was used to prepare cDNA inserts for sequencing. A 
master mix of, 4.8ul M13 reverse primer (M13R) (2uM) was prepared in 451.2ul MOhm 
(nuclease free) water. Of the 456ul total volume, 3.8ul aliquots were pipetted individually 
into each well. Aliquots of 1.2ul from the thawed and pulsed RCA plate were pipetted into 
each well using the multi-channel pipetter. The wells were sealed and the plate was pulse 
spun for 30 seconds, wrapped in cellophane and aluminum foil, labeled with a pre-assigned 
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ID number and submitted on dry ice to the Hubbard Center for Genome Studies (HCGS) at 
the University of New Hampshire for sequencing of the differentially expressed RDA 
transcripts in the ABB 130 genetic analyzer. The Ml3 Reverse primer (5' 
GGAAACAGCTATGACCATG 3') was chosen to amplify the target inserts from the pBS 
Vector (63). The results were provided from the Genome Center in digital file format, 
which included the individual sequences, quality scores in "fasta" format, and 
chromatograms to help determine the quality of the sequences (63). 
Sequence Analysis and Characterization of Differentially Expressed Products 
To begin analysis of the 2626 sequences provided by the Hubbard Genome Center, 
the VecScreen program within the National Center for Bioinformatics (NCBI) data base, 
provided the ability to flank nucleotide sequences for vector contamination or M13R 
primer and to determine the quality of the nucleotide sequences. The process began with 
uploading a sequence into VecScreen to look for vector contamination within the 
nucleotide sequences. The sequences were matched with known vectors in the data base 
and reported as strong, moderate, weak, or suspect. Strong matches were always cut at the 
recommended nucleotide sequence sites, most often removing both sides of the retained 
quality sequence. 
DNAClub is an open freeware program created by Xiongfong Chen at 
http://128.84.203.244 while a student at Cornell University. This program was used to 
highlight and cut the identified vector nucleotide sequences that were flanked by 
VecScreen. This program also allowed one to search for the GATC restriction sites and 
verify a match with VecScreen before removing nucleotide sequences. In addition, this 
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program provided the ability to search for all GATC sites throughout the sequence to 
determine whether more than one sequence was ligated together at the sticky ends. This 
was the case more often than not, and allowed for individual analysis in a later step to 
search for and identify multiple genes within a single sequence. 
Matches that were suspect in VecScreen, were cross evaluated using FinchTV 
Version 1.4.0. located at www.geospiza.com. Finch TV is a very useful program that 
provides a chromatogram of the nucleotide sequence patterns displaying peaks and changes 
that help to further confirm the quality of a sequence that is suspect. Patterns that 
consistently revealed strong peaks, yet were identified as suspect in VecScreen, were 
retained for further analysis. Sequences that revealed small or rounded peaks or many 
changes in the size and shape of peaks were considered poor quality and were discarded. 
Once sequences were evaluated and determined to be quality sequences, they were 
trimmed and saved in a file later to be queried against a database of known gene sequences. 
The Basic Local Alignment Search Tool (BLAST) or BLASTn located within NCBI's data 
base was used to match quality nucleotide sequences with known genes and identify 
potential proteins for the sequences. E-values established in the database were used to 
indicate a level of confidence between matches. A typical cutoff used in this lab was e-4 or 
less. After much discussion a more conservative cutoff of 
e-10- or less was adopted for this research, to indicate greater confidence that a match was 
not by chance. Gene sequences meeting the criteria were accepted as quality sequences. 
Those that were matched with a known gene sequence and met the e-value were 
"identified" genes. Those that were quality sequences but didn't meet the e-value criteria 
of a quality match in BLASTn remained "unidentified". 
52 
Sequences that were labeled as "null" had been either Vec-screened and/or 
underwent BLASTn and were identified as vector or nothing at all, had a poor 
chromatogram, and or a high e-value. 
Annotation, Placement. Regulation and Interactions of Genes 
The MetaCore Software Program located at www.Genego.com is a licensed online 
database that incorporates a systems biology approach to fully annotate and link genes of 
interest to hundreds of available metabolic pathway maps. This approach, provides visual 
analysis of the placement of genes, their interactions and the cascade of events that result in 
a given pathway. Detailed descriptions of the pathways are linked directly to the pathway 
maps. In addition, the individual genes in a given pathway map are linked to a wealth of 
information regarding annotation, gene-gene interactions, and metabolic functions within a 
given pathway. Some of the additional benefits available with MetaCore include, detailed 
descriptions of multiple functions that many of the genes are known to participate in, links 
to known diseases, pharmaceutical research, NCBI, and Pub Med's database, as well as the 
use of E-Z search engines to access gene information. MetaCore also offers the ability to 
build direct networks (which include all the genes known to participate between the 
selected genes of interest) or indirect networks (only displays selected genes of interest), 
and the ability to create custom pathway maps between selected genes (not accessed during 
this project). 
Once genes were identified in NCBI's BLASTn database, they were then retained 
in excel to be later analyzed further for their potential role in initiation and progression. 
MetaCore was utilized to fully annotate genes of interest, and to determine any gene-gene 
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interactions, and regulation within metabolic pathways in order to, distinguish between 
genes potentially involved in initiation and/or progression of atherosclerosis from those of 
normal development. Some of the candidate genes were also compared with unpublished 
in-vitro and in-vivo work conducted by Anderson (63) in this laboratory and are presented 




A total of 2304 cloned DPs were selected for further determination of their 
nucleotide sequences. Table 5, includes the raw sequence data, as well as Vector-Trimmed 
and BLASTed quality sequences from each of the three RDA comparisons of differentially 
upregulated DPs. Of the 2304 possible clones, 70 of the pBluescript (pBS) vectors lacked 
cDNA inserts. The remaining 2234 clones, resulted in a total of 2556 quality sequences. 
The unusual find of 111% quality sequences was due to occasions when more than one 
insert was ligated together at their GATC sticky ends within a pBS vector. Of the total 
number of quality sequences that were accepted, 2270 differentially upregulated sequence 
tags (ESTs) were identified using BLASTn leaving the remaining 286 sequences as 
unidentified. 
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Table 5 represents the three ages that were compared against one another. Comparison one (C-1) lday 
verses 6 weeks (lday:6wks), comparison two (C-2) lday verses 6 months (lday:6mos), and comparison 
three (C-3) 6 weeks verses 6 months (6wks:6mos). 
KEY: Raw data and BLAST results 
Plate = ideal total # inserts per 384 wells/clones per age per comparison 
Mean # bp +/- SEM raw = average # bp before Vec trimmed 
# NULL: is # of wells or clones that lack inserts 
%Nuf is % based on # absent inserts / # wells/clones 
# Accepted: = # of quality inserts accepted (after Vec trimmed and BLASTed) 
% accepted: is based on actual t inserts accepted / # wells/clones 
Mean # bp +/• SEM query: average # bp after Vec Trimmed & before BLASTed 
# indentified is # inserts Vec trimmed & BLASTed & identified 
% identified: is % based on # accepted (# identified/# accepted) 
# unidentified: is # inserts Vec trimmed & BLASTed but remained unidentified (is a quality insert with an e-value of > e-10) these are novel sequences not in data base 
% unidentified is % based on # accepted 
Presented in the following six tables, are lists of the differentially expressed genes 
from each of the three comparisons. Each of the tables, Table 6a and 6b, C-1 (1 day:6 
weeks), Table 7a and 7b, C-2 (1 day:6 months) and Table 8a and 8b, C-3 (6 weeks:6 
months) include the combined data from the four plates that were analyzed for each age 
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comparison, using NCBI's BLAST program, and presents the genes that were differentially 
upregulated between the ages compared. The colored asterisks in each of the six tables 
represent the rare instances when difference products were upregulated in both ages within 
a comparison. Gene's upregulated in this manner are color coded by an asterisk next to 
their gene name, so they can be easily tracked between the tables. 
Totals for each age compared are located at the bottom of each column. The first 
represents the mean base pair length of all the quality sequences that were Vec-Screened 
and BLASTed. The "identified" represents the total number of quality sequences that were 
identified in BLAST (meeting the e-value cut off of e-10 or <) and includes annotated as 
well as non-annotated genes. The unidentified quality ESTs followed since they did not 
meet the e-value criteria of acceptance in NCBI. Since the unidentified ESTs did not meet 
the e-value criteria, it is not known whether any of the ESTs are the same or are all 
different genes. Additional efforts required to identify these ESTs were beyond the scope 
of this thesis. The total number of ESTs for an age includes the combined totals of the 
identified as well as the unidentified difference products. The total number of identified, 
unique, non-redundant sequence tags is represented in each of the tables as, "total number 
of identified non-redundant transcripts". Finally, in the instances when the actual "gene 
name" for the identified genes was not available, NA was used in the appropriate column. 
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Table 6a: Differentially Expressed Genes, Comparison 1 (1 Day Versus 6 Weeks) 
Ortholog (C-1 1day Merged plates A-D} 
lumican (LUM) 
clone ChEST85g22 
collagen, type I, alpha 2 (COL1A2) 
telokin 
actin, alpha 2, smooth muscle, aorta (ACTA2) 
similar to SEC61 gamma (LOC776639) 
clone ChEST874k20 
1B-3866 cytochrome c oxidase subunit I (COI) 
BAC clone CH261-10P22 
leucine rich repeat containing 17 
ATPsynthase FO subunit 8 (ATP8) gene 
dermatan sulfate proteoglycan decorin 
fdxl gene and 4 orf s 
hypothetical LOC424163 (LOC424163) 
vascular smooth muscle alpha-actin (ACT-4) 
ATP synthase FO subunit 8 and 6 (ATPase 8, 6), 
BAC clone TGMCBa-23H12 
klral 7 mRNA for lectin-like transmembrane protein, Ly49q1 isoform (CDR-1) 
clone 0064p0012D12 putative ribosomal protein 
collagen, type VIII, alpha I (COL8A1) 
fatty acid binding protein 4, adipocyte (FABP4) 
hypothetical LOC424163 
fk506 binding protein 9, 63 kDA (FKBP9) 
myoglobin gene 
NADH dehydrogenase subunit 4 gene 
neomycin resistance cassette pNeo4 NeoTet (neoTet) 
microsatellite marker vemos44 
CR1 gene for chicken repeat 1 
has operon deletion mutant 








































































TOTAL (ESTj of 384 wetts I 450 
TOTAL # identified non-redundant transcripts | 31 
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Table 6b: Differentially Expressed Genes, Comparison 1 (6 Weeks Versus 1 Day) 
O r t h o l o g <C-1 S w k s SVSerged p i a t e s A - D ) 
heat shock protein 90 alpha 
BAC clone CH261-126J23 
gelsolin (GSN) 
clone 0064P0021C06 spermidine/spermine N1-acetyltransferase 
similar to nbosomal protein L3 (LOC771432) 
hypothetical LOC415891 (LOC415891 ) 
myosin heavy chain II smooth muscle ( M Y H 1 1 ) _ 
clone ChEST398a16 (RPL32) 




eukaryotic translation initiation factor 3 subunit H (EIF3H) 
rho-assoaate coiled-coil forming kinase 1 (ROCK1) 
chromogramn B (secretogramn 1) (CHGB) 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX5) 
hemoglobin alpha-globin chain 
lymphocyte antigen 6 complex locus E (LY6E) 
similar to NPD014 protein (NPD014) 
nbosomal protein S3A (RPS3A) 
splicing factor argmine/senne-nch 10 (transformer 2 homoloq drosophila) (SFRS10) 
splicing factor argmine/senne-nch 6 (SFRS6) 
beta2-microqlobulm 




similar to yeast nbosomal protein S28 homologue (LOC427323) 
alpha-tropomyostn gene exons 9c 9d and complete cds alternatively spliced 
clone 0062P0001C01 putative high-mobility group nucleosome binding domain 1 variant 1 
beta-actin 
acidic (leucine-nch) nuclear phosphoprotein 32 family member A (ANP32A) 
alpha thalassemta/mental retardation syndrome X-linked (ATRX) 
BAC clone CH261-114A20 
clone ChEST398a16 
destnn (actin depolymenzing factor) (DSTN) 
jagged 1 (Alaqille syndrome) (JAG1) 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 42kDa (NDUFA10) nuclear 
similar to B-aqgressive lymphoma 2B 
RPS6 mRNA for nbosomal protein S6 
vimentin (VIM) 
similar to collaqen alpha-2(IV) chain (LOC418752) 
hypothetical LOC423192 (LOC423192 ) 
hypothetical LOC423602 (LOC423602) 
hypothetical protein L O C 7 7 0 9 0 9 
similar to SDF3 (LOC771608) 
clone 0058P0011D09 putative beta 1 integnn binding protein 2 vanant 1 
12S nbosomal R N A g e n e 
B-cell translocation gene 1 anti-proliferative (BTG1) 
calmodulin 1 (phosphorylase kinase delta) (CALM1) 
chaperonm containing T C P 1 subunit 8 (theta) (CCT8) 




cytochrome oxidase subunit I (COI) 
sp 28150kinawa mitochondrial genomic D N A 
cleavage stimulation factor 3 pre-RNA subunit 1 5 0 k D a ( C S T F 1 ) 
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) 
eukaryotic translation tnititiation factor 4A isoform 2 (EIF4A2) 
eukaryotic translation initiation factor 5 (EIF5) 
FYN oncogene related to SRC F G R YES (FYN) 
hect domain and RLD 2 (HERC2) 
heterogeneous nuclear nbonucleoprotein D-like (HNRPDL) 
low density lipoprotein receptor-related protein associated protein 1 (LRPAP1) 
lumican (LUM) 
mitochondnal nbosomal protein L27 (MRPL27) 
pumiho homolog 2 (drosophila) (PUM2) 
ring finger protein 11 (RNF11) 
nbosomal protein L5 (RPL5) 
nbosomal protein L6 (RPL6) 
clone 0058P0031F07 putative nbosomal protein S3 
splicing factor argmine/senne-nch 1 (SFRS1) 
T cell receptor delta chain (TCRD) pseudogene 
W D repeat domain phosphomositide interacting 2 (WIPI2) 
clone 0058P0047C07 putative S N F 7 domain containing 2 vanant 2 
clone 0069P0004A06 transcriptional regulator Id2-like 
clone 0064P0010H05 high-mobility group nucleosome binding domain 1 variant 1-like 
clone 0061P0031D11 matnxGla- l ike 
steroid dehydrogenase 
invanant chain (h) 














































7 7 0 9 0 9 
771608 



























T C R D 
WIPI2 
clone 0 0 5 8 P 0 0 4 7 C 0 7 
clone 0069P0004A06 





M L A N IBP} 
z~ ^ 
UNIDENTIF IED 
T O T A L (EST1 of 3 8 4 wel ls 
T O T A L # identif ied non-redundant t ranscr ipts 
















































Table 7a: Differentially Expressed Genes, Comparison 2 (1 Day Versus 6 Months) 
Ortholog (C-2 1day plates A-D) 
collagen, type I, alpha 2 (COL1A2) 
clone ChEST874k20 
fibulin 5 (FBLN5) 
similar to SEC61 gamma(LOC776639) 
keratin sulfate proteoglycan lumican 
nephroblastoma overexpressed (NOV) 
FK506 binding protein 9, 63 kDa (FKBP9) 
telokin myosin, light chain kinase (MYLK) 
clone 0062P0005D06 putative 40S ribosomal protein S8 
fibronectin 1 (FN1) 
clone 0063P0029G01 putative RHoA GTPase variant 3 
ATP synthase FO subunit 8 (ATP8) 
cytochrome c oxidase subunit I (COI) 
mitochondrial genomic DNA 
collagen, type III, alpha 1 (COL3A1) 
leucine rich repeat containing 17 (LRRC17) 
ras homolog gene family, member A (RHOA) 
clone 0058P0007G11 putative peroxiredoxin 1 variant 3 
16S ribosomal RNA 
calmodulin 1 (phosphorylase kinase, delta) (CALM1) 
carboxypeptidase E (CPE) 
mitochondrion 
PG-M mRNA for proteoglycan 
ribosomal protein L7 (RPL7) 
hypothetical LOC424163 
clone 0061P0024E07 putative sm like protein U6 snRNA-associated Sm-like protein 
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1 
clone 0063P0009H02 putative proteosome maturation protein 
clone 0058P0011D09 putative beta 1 integrin binding protein 2 variant 1 
BAC clone CH261-10P22 
BAC clone CH261-147F20 
BAC clone CH261-79I12 
non-muscle caldesmon 
cell division cycle 2, G1 to S and G2 to M (CDC2) 
similar to Methylosome subunit plC1n (chloride conductance regulatory protein IC1n) 
clone ChEST433n1 
cloneChEST587b19 
type VI collagen alpha-2 subunit 
dermatan sulfate proteoglycan decorin 
destrin (actin depolymerizing factor) (DSTN) 
clone 0062P0005H11 putative eukaryotic translation initiation factor 1 variant 1 
H3 histone, family 3B (H3.3B) 
similar to otoancorin (LOC771927) 
clone 0063P0009H02 putativee proteosome maturation protein 
ornithine decarboxylase antizyme 1 (OAZ1) 
similar to yeast ribosomal protein s28 homologue (LOC427323) 
ribosomal protein S3A (RPS3A) 
actin, alpha 2, smooth muscle, aorta (ACTA2) 




















































Z^, "' '£X' 
UNIDENTIFIED 
TOTAL fESTi of 384 weils 
































Table 7b: Differentially Expressed Genes, Comparison 2 (6 Months Versus 1 Day) 
Ortholog (C-2 6mos plates A-D) 
heat shock protein 90 alpha 
similar to myosin-11 (Myosin heavy chain, gizzard smooth muscle) (LOC777204) 
BAC clone CH261-117C7 
calnexin (CANX) 
actin, alpha 2, smooth muscle, aorta (ACTA2) 
lumican (LUM) 
myosin, light chain kinase (MYLK) 
16S ribosomal ma 
CD36 molecule (thrombospondin receptor) (CD36) 
mma for tau-crystallin/alpha enolase 
clone 0057P0001H01 calmodulin variant 1-like 
cytochrome oxidase subunit II (COM) 
Rho-associated, coiled-coil containing protein kinase 1 (ROCK1) 
12S ribosomal ma 
ATP synthase F0 subunit 8 (ATP8) 
clone 0058P0017H07 
similar to CD59 protein (LOC423148) 
mitochondrial genomic DNA 
mitochondrial DNA 
phosphodiesterase 5A, cGMP-specific (PDE5A) 
clone 0058P0057E07 ribosomal protein L32-like 
similar to bullous pemphigoid antigen 1, 230/240kDa (LOC421884) 
acyl-CoA synthetase long-chain family member 1 (ACSL1) 
beta-actin (ACTB) 
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A) 
similar to asponn (LOC415954) 
BAC clone CH261-138K4 
BAC clone CH261-187N23 
clone Pgp29 microsatellite sequence 






cytochrome c oxidase subunit I (COI) 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, x-linked (DDX3X) 
eukaryotic translation initiatin factor 4A, isoform 2 (EIF4A2) 
fatty acid binding protein 4, adipocyte (FABP4) 
mitochondrion 
similar to phospholipase C beta 4, transcript variant 2 (LOC416730) 















































TOTAL (EST) of 3B4 wells 





























Table 8a: Differentially Expressed Genes, Comparison 3 (6 Weeks Versus 6 Months) 
Ortholoq {C-3 6wk A-D compared) 
clone 0064P0021C06 spermadine/spermine N1-acetyltransferase variant 1-like 
BAC clone CH261-126J23 from chromosome ul 
similar to yeast ribosomal protein S28 
ribosomal protein S3A (RPS3A) 
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1 
qelsolin (GSN) 
similar to ribosomal protein L3 (LOC771432) 
prohibitin 2 (PHB2) 
similar to coactosin-like 1 (dictyostelium) (LOC768420) 
nucleoside diphosphate kinase 
finished cDNA, clone ChEST14214 
NADH hydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa (NDUFA10), 
ras homoloq qene family, member A (RHOA) 
ribosomal protein L9 (RPL9) 
S-phase kinase-associated protein 1 (SKP1) 
eukaryotic translation initiation factor 3, subunit H (EIF3H) 
clone 0058P0007G11 putative peroxiredoxin 1 variant 3 
similar to SDF3 (LOC771608) 
BAC clone CH261-77K20 
cytochrome oxidase subunit II (COII), mitochondrial 
collaqen, type I, alpha 2 (COL1A2) 
clone 0061P0016C08 putative actin related protein 2/3 complex subunit 2 
actin, beta (ACTB) 
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A) 
clone ChEST611b2 
clone 0062P0005H11 putative eukaryotic translation initiation factor 1 variant 1 
similar to B-aqqressive lymphoma 2B (LOC424266) 
clone 0061P0001E09 putative Yip1 domain family member 1 
mitochondrion 
chaperonin containinq TCP1, subunit 8 (theta) (CCT8) 
cyclin-dependent kinase inhibitor p27 Kip1 
clone 0061P0031D11 matrix Gla-like 
ribosome bindinq protein 1 homoloq 180kDa (doq) (RRBP1) 
ribosomal protein L4 (RPL4) 
ribosomal protein S23,11 days embryo whole body cDNA, RIKEN full-lenqth 
vimentin (VIM) 
hypothetical protein LOC770045 
clone 0061P0022F12 putative creatine kinase B variant 1 
clone 0064P0012G12 RIKEN cDNA 0610039A15-like 
similar to adenylate kinase (EC 2.7.4.3) (LOC428227) 
chromosome 12 open readinq frame 49 (c12orf49) 





similar to collaqen alpha-2 (IV) chain 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5) 
DnaJ (Hsp40) homoloq, subfamily A, member 1 (DNAJA1) 
destrin (actin depolymerizinq factor) (DSTN) 
GNAS complex locus, transcript variant 2 (GNAS) 
similar to qlycoqen synthase kinase 3 beta (LOC418335) 
lectin associated matrix protein (hLAMP-1) 
similar to microfibrillar associated protein 5 (LOC418256) MFAP5 
proline-rich nuclear receptor coactivator 1 (PNRC1) 
rinq finqer protein 11 (RNF11) 
ribosomal protein L5 (RPL5) 
ribosomal protein S6 (RPS6) 
transmembrane emp24 protein transport domain containinq 5 (TMED5) 

































































TOTAL (EST) OF 384 












































Table 8b: Differentially Expressed Genes, Comparison 3 (6 Months Versus 6 Weeks) 
Ortholog (C-3 6mos A-D compared) 
heat shock protein 90kDa alpha (cytosolic), class A member 1 (HSP90AA1) 
lumican (LUM) 
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2) 
actin, alpha 2, smooth muscle, aorta (ACTA2) 
myosin, heavy chain 11, smooth muscle (MYH11) 
fibroblast myosin light chain kinase 
enolasel, (alpha) (EN01) 
BAC clone CH261-117C7 
acyl-CoA synthetase long-chain family member 1 (ACSL1) 
ATP synthase FO subunit 8 (ATP8) 
BAC clone CH261-126J23 
clone ChEST85g22 
16S nbosomal RNA gene, partial sequence; tRNA-leu gene, complete sequence; 
NADH dehydrogenase subunit 1 (ND1) gene 
similar to 0TTHUMP00000028984 (LOC418017) 
hypothetical LOC419017, transcript vanant 1 (LOC419017) 
BAC clone CH261-16J12 
BAC clone CH261-19B3 
BAC clone TAM31-16o5 
BAC clone TGMCBa-49H12 
CD151 molecule (Ralph blood group) (CD151) 
clone 0061P0022F12 putative creatine kinase B variant 1 
mitochondnon 
mitochondrial genomic DNA 
ZMUC 125434 ornithine decarboxylase (ODC) 
odd-skipped related 1 (drosophila) (OSR1) 
GTP-specific succinyl-CoA synthetase alpha subunit (SCS) 































TOTAL |ESTS of 384 




















Chi square analysis was initially used to determine statistical differences (using a p-
value of < 0.05) and was required to establish regulation patterns between the ages 
compared, prior to uploading into MetaCore. Because the RDA method in and of itself 
enriches only for sequences that are differentially expressed, genes that were upregulated 
between the comparisons were significant by nature of the method. This ability of the 
RDA method to detect and selectively enrich transcripts of low copy number speaks for the 
level of sensitivity of the method (71) and negated any further reason for using chi square 
analysis to assist in the interpretation of the results. 
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The largest number of identified genes (presented in Table 9) was observed at 6 
months of C-3 with 434 gene transcripts followed by 419 genes at 6 weeks of C-l. The 
greatest number of unidentified transcripts, (109) was observed at 1 day of C-l, followed 
by 87 transcripts at 1 day of C-2. In C-3, only 16 unidentified transcripts were found at 6 
months, which was the lowest number of unidentified transcripts of all the ages 
compared. This is perhaps because more work to identify genes, has been completed on 
older vertebrates as compared to younger vertebrate animals. In C-l and C-3, both 1 day 
and 6 months respectively contained the greatest number (450) of identified and un-
identified expressed sequence tags (ESTs) combined. The largest number (83) of unique, 
non-redundant transcripts was observed at 6 weeks in C-l when compared to 1 day. In 
contrast, 27 genes at 6 months of C-3 was the lowest number of non-redundant transcripts 
found in an age group compared. 
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When distinguishing between genes involved in the disease process, and those that 
were expressed as a result of normal development, the genes that were expressed in the 
highest number of copies were not necessarily the primary focus. Copy number provides 
one perspective into the understanding of which genes may be key players participating in 
atherosclerosis. In fact, as demonstrated in monogenic diseases, a single gene may be 
responsible for kicking off a cascade of events. Given the extensive time required to 
evaluate each of the 291 differentially expressed, non-redundant transcripts in this 
experiment, it became necessary to develop criteria to effectively address the current 
hypothesis and select the most likely candidates involved in atherosclerotic disease. 
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Genes that were differentially upregulated at 1 day, 6 weeks, and 6 months when 
compared to each of their respective ages are presented in Tables 10,11, and 12, and 
comprised the first criteria of distinguishing between genes that are potentially involved in 
initiation and those that participate in progression. Genes that were differentially 
upregulated specifically at 1 day when compared to 6 weeks and 6 months are regarded as 
representing the earliest stage of the disease. This may in fact be the most important stage 
when distinguishing initiation from that of progression. Table 10 provides a combined list 
of the 55 genes that were differentially upregulated at only 1 day when compared to 6 
weeks and 6 months. The 7 genes that were differentially upregulated at 1 day in both 
C-l and C-2 may actually represent the gene or genes that are related to initiation of 
atherosclerosis. The genes that were exclusive to 1 day in this case include, SEC61 
Gamma (SEC61G), FK 506 binding protein9 (FKBP9), clone ChEST874k20, BAC 
CH261-10P22, Leucine rich repeat containing 17 9LRRC17), Decorin (DCN), and 
hypothetical protein LOC424163. 
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Table 10: 
Genes Differentially Upregulated at 1 Day When Compared to 6 Weeks & 6 Months 
Qrftioiog ( W Way versus 6weeksj 
similar to SEC61 gamma (LOC776639) 
clone ChEST874k20 
BAC done CH261-10P22 
leucine nch repeal containing 17 
deimatan sulfate proteoglycan deconn 
hypothetical LOC424163 (LOC424163) 
vascular smooth muscle alpha-actin (ACM) 
ATP synthase FO subumt 8 and 6 (ATPase 8,6), 
BAC done TGMCBa-23H12 
Wra17 mRNA for ledm-like transmembrane protein, Ly49q1 isoform (CDR-1) 
done 0064pD012D12 putative nbosomal protein 
collagen, type VIII, alpha I (C0L8A1) 
hypothetical LOC424163 
W binding protein 9 63 kDA (FKBP9) 
myoglobin gene 
neomycin resistance cassette pNeo4 NeoTel (neoTet) 
microsatellite marker vemos44 
CR1 gene for chicken repeat 1 
fdxl gene and 4 orf s 
has operon deletion mutant 































Orthoiog (C-2 W a y versus Smomfa) 
clone ChEST874k20 
similar to SEC61 gamma(LOC776639) 
nephroblastoma overexpressed (NOV) 
fk506 binding protein 9,63 kDA (FKBP9) 
done 0062P0005D06 putative 40S nbosomal protein S8 
fibronectm 1 (FN1) 
done 0063P0029G01 putative RHoA GTPase variant 3 
collagen, type III, alpha 1 (C0L3A1) 
leucine nch repeal containing 17 (LRRC17) 
done 0058P0007G11 putative perouredoxin 1 vanant 3 
caitjoxypeptidaseE(CPE) 
PG-M mRNA for proteoglycan 
nbosomal protein L7(RPL7) 
hypothetical LOC424163 
done 0061P0024E07 putative sm like protein U6 snRNA-associated Sm-like protein 
done 0063P0030D07 putative solute earner family 25 member 6 variant 1 
done 0063P0009H02 putative proteosome maturation protein 
done 0058P0011D09 putative beta 1 integnn binding protein 2 variant 1 
BAC done CH261-10P22 
BAC done CH261-147F20 
BAC done CH261-79I12 
non-muscle caldesmon 
cell division cyde 2, G1 to S and G2 to M (CDC2) 
similar to Methylosome subumt pICIn (chloride conductance regulatory protein IC1 n) 
,(l(C1n)) (chloride channel, nudeotide sensitive 1A) (LOC425500) 
> n e C h E S T 4 3 3 n 1 
|doneChEST587b19 
| type VI collagen alpha-2 subunit 
Idermatan sulfate proteoglycan deconn 
H3 histone, family 3B (H3 3B) 
similar to oioanconn (L0C771927) 
done 0063P0009H02 putativee proteosome maturation protein 
ornithine decarboxylase anbzpe 1 (0AZ1) 

















































Table 11 represents the 60 genes that were differentially upregulated at 6 weeks 
when compared to 1 day and the 47 genes differentially upregulated at 6 weeks in C-3. 
Since these genes were not found to be upregulated until 6 weeks of age, they are likely 
contributors in the progression of atherosclerosis. Of the 107 genes that were differentially 
upregulated at 6 weeks, only 16 were differentially upregulated at 6 weeks when compared 
to both ages in C-l and C-3. They appear to be distinct only to 6 weeks and include 
Gelsolin,(GSN), Spermidine/spermine Nl-acetyltransferase (SATl), Ribosomal protein L3 
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(RPL3), Ribosomal protein L4 (RPL4), Eukaryotic translation initiation factor 3, subunit H 
(EIF3H), Dead (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX5), Cyclin-dependant kinase 
inhibitor p27 kipl (CDKN1B), Ribosomal protein S28 (RPS28), Tropomyosin-alpha 
(TPMl), Similar to B-aggressive lymphoma / Poly (ADP-ribose) polymerase (PARP14), 
Ribosomal protein S6, (RPS6), Vimentin (VIM), Chaperonin containing TCPl, subunit 8 




Genes Differentially Upregulated at 6 Weeks When Compared to 1 Day & 6 Months 
Ortholog |C-1 fiweeks versus 1eay) 
gelsolm (GSN) 
clone 00&4P0D21CO6 spermidine/spermine N1-acetyltransferase 
similar to nbosontal protein L3 (LOC771432) 
hypothetical LOC415891 (LOC415891) 
nbosomal protein L4 (RPU) 
doneChEST118|5 
eukaryotic translation initiation factor3 subumt H (EIF3H) 
chromogranin B (secretogramn 1) ICHGB) 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX5) 
hemoglobin alpha-globm chain 
lymphocyte antigen 6 complex locus E JLY6E) 
similar to NPD014 protein (NPD014) 
splicing factor arginine/serine-ncti 10 (transformer 2 homolog drosophila) (SFRS10) 
splicing fedor argmine/senne-nch 6 (SFRS6) 
doneChEST1007e10 
bela2-m:croglobulin 
cydrrvdependent kinase inhibitor p27 Kip1 
similar to yeast nbosomal protein S28 homologue (LOC427323) 
alpha-tropomyosm gene, exons 9c 9d, and complete cds alternatively spliced 
clone C362P0D01031 putative high-mobility group nudeosome binding domain 1 vanant 1 
alpha lhalassemia/mental retardation syndrome X-linked (ATRX) 
BACdoneCH261-114A20 
lagged 1 (Alagille syndrome) (JAG1) 
similar to B-aggresswe lymphoma 2B 
RPS6 mRNAfor nbosomal protein S6 
vimentin (VIM) 
similar to collagen alpha-2(IV) chain (L0C418752) 
hypothetical LOC423192 (LOC423192) 
hypothetical LOC423602 (LOC423602) 
hypothetical protein LOC770909 
similarto SDF3 (LOC771608) 
B-cell translocation gene i anti-prolrferative (BTG1) 
chaperonin containing TCP1, subunit 8 (theta) (CCT8) 




cleavage stimulation factor, 3' pre-RNA subunit 1 50kDa (CSTF1) 
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) 
eukaryotic translation initiation factor 5 (EIF5) 
FYN oncogene related to SRC FGR, YES (FYN) 
hed domain and RLD 2 (HERC2) 
heterogeneous nudear nbonudeoprotein Dfike (HNRPDL) 
low densriy lipoprotein receptor-related protein associated protein 1 (LRPAP1) 
mitochondnal nbosomal protein 127 (MRPL27) 
pumilio homolog 2 (drosophila) (PJM2) 
ring finger protein 11 (RNF11) 
nbosomal protein L5 (RPU) 
nbosomal protein L6 (RPL6) 
clone 0058P0031F07 putative nbosomal protein S3 
splicing factor, argmine/senne-nch 1 (SFRS1) 
T cell receptor delta chain (TCRD) pseudogene 
WD repeat domain, phosphoinositide interacting 2 (W1PI2) 
clone 0058P0047C07 putative SNF7 domain containing 2 vanant 2 
clone 0069P0004A06 transcnptional regulator Id2-like 
clone 0064P0010H05 high-mobility group nudeosome binding domain 1 vanant 1-like 
clone 0061P0031D11 matnx Gla-like 
steroid dehydrogenase 
mvanant chain (li) 






























































Copy # l O r t h o l o g (C-3 Sseeks versus faonths) 
4 3 l d o n e 0064P0021C06spemiadine/spemiine N1-acetyltransferase variant Hike 
34j|similarto yeast nbosomal protein S28 homologue (LOC427323) 




similarto nbosomal protein L3 (LOC771432) 
5Pprohibitin2(PHB2) 




















nucleoside diphosphate kinase 
finished cDNA done ChEST14214 
nbosomal protein L9(RPL9) 
S-ptiase kinase-associated protein 1 (SKP1) 
eukaryotic translation initiation factor 3 subunit H (EIF3H) 
done 0058P0007G11 putative peroxiredoxin 1 vanant 3 
similarto SDF3 (LOC771608) 
BACdoneCH261-77K20 
done 0061P0016C08 putative actin related protein 2/3 complex subunit 2 
similar to B-aggressive lymphoma 2B (LOC424266) 
done 0061P0001E09 putative Yip1 domain family member 1 
chaperonin containing TCP1 subunit 8 (theta) (CCT8) 
cydin-dependent kinase inhibitor p27 Kip1 
done 0061P0031D11 matnx Gla-like 
nbosome binding protein 1 homolog 180kDa (RPBP1) 
nbosomal protein L4 (RPL4) 
vimentin (VIM) 
hypothetical prolan L0C770045 
done 0061P0022F12 putative creatine kinase B vanant 1 
done 0064P0012G12 RIKEN cDNA 0610039A15-like 
similar to adenylate kinase (EC 2 7 4 3) (LOC428227) 
chromosome 12 open reading frame 49 (c12orf49) 





similar to collagen alpha-2 (IV) chain 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5) 
DnaJ (Hsp40) homolog subfamily A member 1 (DNAJA1) 
GNAS complex locus transenpt vanant 2 (GNAS) 
similarto glycogen synthase kinase 3 beta (LOC418335) 
lectin associated matnx protein (hLAMP-1) 
similarto microfibrillar associated protein 5 (LOC418256) MFAP5 
proline-nch nudear receptor coadivator 1 (PNRC1) 
nng finger protein 11(RNF11) 
nbosomal protein L5 (RPL5) 
nbosomal protein S6(RPS6) 
transmembrane emp24 protein transport domain containing 5 (TMED5) 











































































Thirty-seven genes were differentially upregulated at 6 months when compared to 1 
day (C-2) and 6 weeks (C-3) of age respectively and are listed in Table 12. These are 
related to disease progression since they were not differentially upregulated in the previous 
ages. Of the 37 genes only 3, BAC CH261-117C7, Enolase 1 (ENOl) and Acyl-coA 
synthetase long chain family member 1 (ACSL1) were differentially upregulated 
exclusively at 6 months when compared to both 1 day and 6 weeks. 
Table 12: 
Genes Differentially Upregulated at 6 Months When Compared to 1 Day & 6 Weeks 
Oitt iolog (C-2 tenths y e s u s iday) 
BAC done CH261-117C7 
calnexin (CANX) 
CD36 molecule (thromfcospondin receptor) (CD36) 
mrna for tau-crystallin/alpha enolase 
clone 0057P0001H01 calmodulin variant Hike 
done0058P0017H07 
similar to CD59 protein (LOC423148) 
phosphodiesterase 5A, cGMP-specific (PDE5A) 
similarto bullous pemphigoid antigen 1,230/240kDa (LOC421884) 
acyl-CoA synthetase long-chain family member 1 (ACSL1) 
similar to asporin (LOC415954) 
BAC done CH261-138K4 
BAC done CH261-187N23 
done Pgp29 microsatellite sequence 




DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, x-linked (DDX3X) 
mitochondnon 


































Ortholog ( W tenths versus fiweeks} 
enolase 1, (alpha) (ENOl) 
BACdoneCH261-117C7 
acyl-CoA synthetase long-chain family member 1 (ACSL1) 
16S liposomal RNA gene, partial sequence; tRNA-leu gene, complete 
sequence; NADH dehydrogenase subunit 1 (ND1) gene 
Similarto 0TTHUMP00000028984 (LOC418017) 
hypothetical LOC419017, transcript variant 1 (LOC419017) 
BAC clone CH261-16J12 
BAC done CH261-19B3 
BAC done TAM31-16o5 
CD151 molecule (Ralph blood group) (C0151) 
done 0061P0022F12 putative creaine kinase B variant 1 
ZMUC125434 ornithine decarboxylase (ODC) 
odd-skipped related 1 (drosophila) (0SR1) 
GTP-spedfic sucdnyl-CoAsynthetase alpha subunit (SCS) 






















The following bar graphs, Figures 2a - 2af provide a pictorial representation of 
genes in a manner that was similar to those listed in tables 10,11, and 12. In addition, 
however, the bar graphs were developed to visually display the regulation patterns of only 
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those genes that were differentially expressed in more than one age comparison, either at 
the same age or at different ages therefore comprising the second criteria. They were then 
grouped as participating in either initiation or progression of atherosclerosis. Given the 
three age comparisons, seven different patterns of regulation were possible and are laid out 
in Table 13. 
Table 13: Patterns of Genes Differentially Expressed in Age Comparisons 


















































Of the 291 genes that were originally identified by BLASTn, 57 genes were 
grouped into one of the seven patterns. While it is interesting to look at the change in 
patterns of expression throughout the three comparisons, it is important to keep in mind 
that the differential expression is unique between the ages compared and cannot necessarily 
be compared to another comparison (age group) or across comparisons. The following 
Figures 4a - 4af represent the upregulation pattern of a given gene within an age group 
compared, as well as patterns of expression across comparisons. 
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Figures 4a - 4af: Upregulation of Genes Within and Across Comparisons: 
Figure 4a: Sec61 Gamma Subunit (SEC61G) Figure 4b: Clone ChEST874k20 
ChEST874k20 
C J CJ\ CJ2 C_2 C_3 C_3 
1Day 6wks 1Day 6mos 6wks 6mos 
Figure 4c: Hypothetical LOC424163 Figure 4d: Decorin (DCN) 
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Figure 4e: FK506 Binding Protein 9 
(FKBP9) 
Figure 4f: Leucine Rich Repeat 
Containing 17 (LRRC17) 
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Figure 4g: BAC CH261-10P22 Figure 5h: Gelsolin (GSN) 
BAC CH261-10P22 
^ j ^ , . - ^ "• 


















Figure 5i: Ribosomal Protein L3 (RPL3) Figure 5j: Spermidine/Spermine 
Nl-actetyltransferase (SATl) 
Figure 5k: Ribosomal Protein S28 (RPS28) Figure 51: Chaperone Containing TCPl, 
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Figure 5m: DEAD (Asp-Glu-Ala-Asp) box Figure 5n: Eukaryotic Translation 
polypeptide 5 (DDX5) Initiation Factor 3, Subunit H (EIF3H) 
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Figure 5o: B-aggressive Lymphoma 2B 
(PARP14) 
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Figure 5u: Vimentin (VIM) Figure 5v: Cyclin Dependant Kinase 
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Figure 6y: Enolase (ENOl) 
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Figure 7cc: Eukaryotic translation 
Initiation Factor 1 (EIF1) 
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Figure 6z: Acyl-CoA synthetase long-
chain family member 1 (ACSL1) 
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Figure 7bb: NADH hydrogenase 
(ubiquinone) 1 alpha subcomplex, 10 
(NDUFA10) 
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Figure 7dd: Ras Homolog Gene Family, 
Member A (RHOA) 
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Figure 7ee: Ribosomal Protein S23 
(RPS23) 
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Figure 7gg: Calmodulin 1 (CALMl) Figure 7hh: Ribosomal Protein S3A 
(RPS3A) 
Figure 7ii: Destrin (DSTN) Figure 7jj: Acidic (leucine rich) nuclear 
phosphoprotein 32, member A (ANP32A) 
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1Day 6wks 1CBy 6m5S 6wks 6mos 
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Figure 8kk: Fatty Acid Binding Muscle, 
Protein 4 (FABP4) 
Figure 811: Fibulin 5 (FBLN5) 
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Figure 8mm: Myosin Light Chain Kinase Figure 8nn: ATP Synthase FO Subunit 8 
(MYLK) (ATP8) 
MYLK 
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Figure 8oo: Actin, alpha 2, Smooth 
Aorta (ACTA2) 
Figure 9pp: Actin, Beta (ACTB) 
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Figure 9qq: Ribosomal Protein L32 
(RPL32) 
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Figure 9ss: Clone ChEST 189kl 1 Figure 9tt: RHO Associate Coiled-Coil 
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Figure 9uu: Clone ChEST 398al6 Figure 9w: Figure 2uu: Heat Shock 
Protein 90 AA1 (HSP90AA1) 
HSP90AA1 
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Figure 9ww: Eukaryotic Translation 
Initiation Factor 4A, Isoform 2 (EIF4A2) 
Figure 9xx: Myosin Heavy Chain 11, 
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Figure lOab: 16S Ribosomal rRNA Figure lOac: NADH Dehydrogenase 
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Figure lOad: Cytochrome Oxidase II (COII) Figure lOae: Lumican (LUM) 
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While examining the differential upregulation of genes within the comparisons, the 
seven patterns of expression that were possible when distinguishing between initiation and 
that of progression can be explained as follows. The first pattern, reflects genes that were 
differentially upregulated exclusively at 1 day when compared to the other two ages. 
Genes exhibiting this pattern are presented in Figures 4a-4g and may be the most 
important genes when looking at whether these genes play a role in initiation of the disease. 
The second pattern of expression was observed in Figures 5h-5w. In this pattern, genes 
were differentially upregulated at 6 weeks when compared to both 1 day and 6 months, 
suggesting early progression. The third pattern observed in Figures 6x-6z, include genes 
that were differentially upregulated exclusively at 6 months, which is suggestive of later 
progression. A fourth pattern that was observed in Figures 7aa-7jj involved genes that 
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were differentially upregulated at both 1 day and 6 weeks. Although this pattern may be 
slightly ambiguous, since they were upregulated at both 1 day and 6 weeks it is possible 
that they serve in initiation of the disease and may participate in early progression. The 
fifth pattern of expression presented in Figures 8kk-8oo reflected genes that were 
differentially upregulated at both 1 day and 6 months. This was rather interesting 
suggesting several possibilities. The differential upregulation at 1 day suggests genes are 
involved in initiation. Since they were upregulated again at 6 months, however, this may 
indicate that these genes are involved in both initiation and progression, or that their role 
was simply that of normal development. Since this pattern does not fit the pattern laid out 
in the objectives, these genes were not considered further for purposes of this thesis. The 
sixth pattern of expression (Figures 9pp-9yy) in which genes were differentially 
upregulated at both 6 weeks and at 6 months of age, indicated involvement in progression 
of the disease. The final and seventh pattern of expression included genes that were 
differentially upregulated in all of the three the ages (Figures lOzz-lOaf). The regulation 
of these genes, presented an ambiguous situation and resulted in not placing them in either 
initiation or progression. 
When looking more closely at the regulation of the genes, beginning with the first 
pattern of expression, in Figure 4a, SEC61G gene was differentially upregulated at 1 day 
when compared to 6 weeks and 6 months of the first two comparisons respectively. This 
was also the case for ChEST874k20, LOC424163, DCN, FKBP9, and LRRC17 and BAC 
CH261-10P22 in Figures 4b-4g. 
Genes fitting the second pattern, included GSN, RPL3, SAT1, RPS28, CCT8, 
DDX5, EIF3H, PARP14, RNFl 1, RPL4, RPL5, RPL6, TPMl, VIM, CDKNIB, and clone 
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0061P0031D11 represented in Figures 5h-5w respectively and were differentially 
upregulated at 6 weeks when compared with both 1 day and 6 months (in C I and C_3). 
In the third pattern, (Figures 6x-6z), CH261-117C7, ENOl, and ACSL1 were 
differentially upregulated at 6 months when compared to both 1 day and 6 weeks 
respectively. In the fourth pattern, Collagen type 1, alpha 2 (COL1A2) in Figure 7aa, was 
upregulated at 1 day when compared to both 6 weeks and 6 months in C_l and C_2. It was 
also differentially upregulated at 6 weeks when compared to 6 months in C_3. Figure 7bb 
shows thatNADH hydrogenase (ubiquinone) 1 alpha subcomplex, 10 (NDUFA10) was 
upregulated in both reciprocal ages at 6 weeks when compared to 1 day, and at 1 day when 
compared to 6 weeks in C-l. It was also upregulated at 6 weeks when compared to 6 
months. Figures 7cc-7ee revealed the differential upregulation of, Eukaryotic translation 
initiation factor 1(EIF1), Ras homolog gene family, member A (RHOA) and Ribosomal 
protein S23 (RPS23) at 1 day when compared to 6 months in C-2, and at 6 weeks, when 
compared to 6 months in C-3 yet no difference in upregulation was observed in C-l. 
Figures 7ff and 7gg showed Clone 0058P0011D09, and Calmodulin 1 (CALM1), were 
differentially upregulated at 6 weeks in C-l as well as at 1 day in C-2. Figures 7hh-7jj 
reflect the upregulation of Ribosomal protein S3 A (RPS3A), Destrin (DSTN), and Acidic 
(leucine rich) nuclear phosphoprotein 32, member A (ANP32A), at 6 weeks when 
compared to both 1 day and 6 months respectively, and were also upregulated at 1 day 
when compared to 6 months in C-2 thus concluding genes that fit the fourth pattern of 
expression. In the fifth pattern of expression, Figure 8kk, Fatty acid binding muscle 
protein 4 (FABP4) was differentially upregulated at 1 day when compared to 6 weeks, and 
at 6 months when compared to 1 day, yet no difference in regulation appeared between 6 
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weeks and 6 months in C-3. Fibulin 5 (FBLN 5) (Figure 811) was differentially 
upregulated at 1 day when compared to both 6 weeks and 6 months and was also 
differentially upregulated at 6 months when compared to 6 weeks. This same pattern of 
regulation that was exhibited by FBLN 5 was also observed for Myosin light chain kinase 
(MYLK), ATP synthetase FO subunit 8 (ATP8), and Actin, alpha 2, smooth aorta 
(ACTA2) (Figures 8mm-8oo) except that, they were also upregulated at 6 months when 
compared to 1 day in C-2. 
Genes that fit the sixth pattern of expression included, Actin, beta (ACTB,) 
Ribosomal protein L32 (RPL32), 12S ribosomal rRNA (12SrRNA), Clone ChEST 189kl 1, 
RHO associate coiled-coil forming kinase 1 (ROCK1), Clone ChEST 398al6, Heat shock 
protein 90 AA1 (HSP90AA1), Eukaryotic translation initiation factor 4A (EIF4A2), 
Myosin heavy chain 11, smooth muscle (MYH11) and CH261-126J23 (Figures 9pp-9yy). 
In Figure 9pp, ACTB was differentially upregulated at 6 weeks when compared to both 1 
day and 6 months, and at 6 months when compared to 1 day in C-2. The genes in figures 
9qq-9uu were all upregulated at 6 weeks when compared to 1 day, and were up again at 6 
months when compared to 1 day, yet there was no difference in regulation between 6 
weeks and 6 months in C-3. HSP90AA1, EIF4A2, and MYH11 (Figures 9w-9xx), were 
all upregulated at 6 weeks when compared to 1 day, and at 6 months when compared to 
both 1 day and 6 weeks. 
The final pattern of regulation, exhibited by genes in Figures lOzz-lOaf was rather 
ambiguous as stated previously, and therefore prevented their placement in either initiation 
or progression of the disease. Genes that comprised this seventh pattern included 
Cytochrome oxidase III (COIII), 16S ribosomal rRNA (16S rRNA), NADH dehydrogenase 
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subunit 4 (ND4), Cytochrome oxidase II (COII), Lumican (LUM), and Cytochrome 
oxidase I (COI). 
Once the 57 genes fitting the 7 different patterns of regulation were made known, 
they were then entered into MetaCore to determine their primary function. Although 
genes' fitting patterns five and seven were excluded from further analysis based on the 
hypothesis, they were included in this step with the hope of providing some understanding, 
as to why the seven groups of genes were differentially upregulated at the time points 
reflected by the seven patterns of regulation. These genes were laid out in table format 
according to the 7 types of expression patterns in Table 14. 
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Table 14: Primary Function of Genes Fitting 7 Patterns of Differential Upregulation 
Seven Patterns of Expression: Gene Function According to MetaCore 
Pattern # & Age 
Differentially Upregulated 
#1: t 1 day 
#2: t 6 weeks 
#3:t 6 months 
#4: 11 day & I 6 weeks 
#5: 11 day & t 6 months 
#6: t 6 weeks & t 6 months 



























































































































muscle contration, receptor, immunity 
? 
? 





Mitochondrial energy production, mRNA splicing, translation 
Translation 





Muscle contraction, calcium modulation dependent & regulating proteins 
Cytoskeletal elements 
cell cycle, kinase 
? 
? 
Glycolysis, cell growth, regulation, differentiation, immunity 
Lipid metabolism 
Connective tissue / matrix integrity 
Mitochondrial energy production 
Translation 
Signal transduction, muscle contraction 
Ribosomal production 
? 
Calcium modulation dependent & regulating proteins, muscle contraction 
Ribosomal production 
Cytoskeletal elements & organization, muscle contraction 
Cell growth, regulation & differentiation, tumor suppressor, transcription 
Lipid metabolism 
Adhesion molecule 
Calcium modulation dependent & regulating proteins, muscle contraction, kinase 
Mitochondrial energy production 
Cell motility, muscle contraction, cytoskeletal elements 




Adhesive molecule, kinase 
? 




Mitochondrial energy production 
Ribosomal production 
Mitochondrial energy production 
Mitochondrial energy production 
Proteoglycan 
Mitochondrial energy production 
According to MetaCore, of the original 57 genes, 46 of them that fit patterns one, 
two, three, four, and six, were annotated and remained genes of interest. Given the 
86 
extensive amount of time that would be necessary to fully characterize each of these 
candidate genes, and in light of the expectations of this project, it was decided that only 
genes that were differentially upregulated exclusively as laid out in Tables 10,11, and 12 
would be further analyzed with the assistance of MetaCore's database. 
Of the 55 genes that were differentially upregulated at lday (Table 10), only the 7 
genes that were differentially upregulated exclusively at 1 day when compared to both 
6weeks and 6months respectively were analyzed further for their potential role in initiation 
of atherosclerosis in the discussion. In addition, 107 genes were differentially upregulated 
at 6weeks, while 37 genes were differentially upregulated at 6months (Tables 11 and 12,). 
Of those, only the 16 genes that were differentially upregulated exclusively at 6weeks 
when compared to both lday and 6months respectively (Table 11), and the 3 genes that 
were differentially upregulated exclusively at 6months when compared to both lday and 
6weeks (Table 12), were analyzed further for their potential role in progression. Genes 
fitting this criterion were then researched further in hopes of understanding their potential 
role in initiation and progression of atherosclerosis, and are presented in Table 15. These 
genes will be discussed further in Chapter four of this report. Some of these annotated 
genes were placed in available pathway maps in MetaCore, and are located in the Appendix 
section. 
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Table 15: Genes Upregulated Exclusively at 1 Day, 6 Weeks, and 6 Months When 
Compared to Their Respective Ages. 


























Function According to MetaCore 
Protein transport protein, necessary for protein translocation in the endoplasmic reticulum and is the central component of the 
protein translocation apparatus of the endoplasmic reticulum (ER) membrane 
Associates with ryanodine receptor (RYR-2) in cardiac muscle SR & may play unique physiological role in excitation-contraction 
coupling in cardiac muscle 
Bone proteoglycan II may affect the rate of fibril formation Small cellular or pericellular matrix proteoglycan that is closely related in 
structure to biglycan protein Is a component of connective tissue, binds to type I collagen fibrils plays a role in matrix assembly & is 
capable of suppressing the growth of various tumor cell lines 
The L3 protein is a component of the large 60S subunit of cytoplasmic nbosomes, that catalyze protein synthesis Ribosomes 
consist of a small 40S subunit and a large 60S subunit Together these subunits are composed of 4 RNA species and approximately 
80 structurally distinct proteins 
The L4 is a componet of the large 60S nbosomal subunit of cytoplasmic nbosomes 
This gene encodes a nbosomal protein that is a component of the large 60S nbosomal subunit The protein belongs to the L18P 
family of nbosomal protein that interacts specifically with the beta subunit of casein kinase II Vanable expression of this gene in 
colorectal cancers, compared to adjacent normal tissues has been observed, 
This gene is a componet of the 40S nbosomal subunit of cytoplasmic nbosomes May play an important role in controlling cell 
growth and proliferation through the selective translation of particular classes of mRNA Belongs to the S6E family of nbosomal 
proteins It is the major substrate of protein kinases in the ribosome, with subsets of five C-terminal serine residues phosphorylated 
by different protein kinases 
The S28 gene encodes a nbosomal protein that is a component of the 40S subunit located in the cytoplasm 
Is a transporter that binds and undergoes conformational changes Catalysis of 2ndary active transfer of sulfate from one side of 
membrane to the other up its concentration gradient 
Is involved in translation of proteins in the cytoplasm 
RNA-dependent ATPase activity The rate of ATP hydrolysis is highly stimulated by single-stranded RNA May be involved in pre-
mRNA splicing DEAD box proteins are characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA 
helicases They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation 
initiation, nuclear and mitochondnal splicing and nbosome and spliceosome assembly Some members of this family are believed to 
be involved in embryogenesis spermatogenesis and cellular growth and division 
Is an important regulator of cell cycle progrssion Involved in G1 arrest Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes 
Positive regulator of cyclin D-dependent kinases such as CDK4 Regulated by phosphorylation and degradation events Positive 
regulation of cellular and developmental processes 
Binds to actin filaments in muscle and non-muscle cells Plays a central role in association with the troponin complex, in the calcium 
dependent regulation of vertebrate striated muscle contraction Smooth muscle contraction is regulated by interaction with 
caldesmon In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments This gene is a member of the tropomyosin 
family of highly conserved widely distnbuted actin-binding proteins involved in the contractile system of striated and smooth muscles 
and the cytoskeleton of non-muscle cells 
Enhances STAT6-dependent transaction (By similanty) Has ADP-nbosyltransferase activity Poly(ADP-nbosyl)ation is an 
immediate DNA damage-dependent posttranslational modification of histones and other nuclear proteins that contnbutes to the 
survival of injured proliferating cells 
Vlmentins are class-Ill intermediate filaments found in vanous non-epithelial cells, especially mesenchymal cells Along with actins 
and microtubules (tubulins) the intermediate filaments represent a third class of well-charactenzed cytoskeletal elements 
Mmolecular chaperone assist the folding of proteins upon ATP hydrolysis Known to play a role in vitro in the folding of actin and 
tubulin Also, known as chaperonin containing TCP1, subunit 8 (theta) 
Contains a RING-H2 f nger motif which is known to be important for protein-protein interactions Has been shown to be induced by 
mutant RET proteins (MEN2A/MEN2B) The germline mutations in RET gene are known to be responsible for the development of 
multiple endocrine neoplasia (MEN) 
Calcium-regulated actm-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments preventing 
monomer exchange (end-blocking or capping) It can promote the assembly of monomers into filaments (nucleation) as well as sever 
filaments already formed 
Multifunctional enzyme that, as well as its role in glycolysis plays a part in various processes such as growth control hypoxia 
tolerance and allergic responses May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve 
as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons Stimulates 
immunoglobulin production May be a tumor suppressor 
Activation of long-chain fatty acids for both synthesis of cellular lipids and degradation via beta-oxidation is an isozyme of the long-
chain fatty-acid-coenzyme A ligase family Converts free long-chain fatty acids into fatty acyl-CoA esters and thereby plays a key 




In the WC pigeon, spontaneous atherosclerosis develops in the absence of known 
risk factors (49) making it an excellent model in which to study underlying genetic factors 
associated with atherosclerosis. In this study, two hundred and ninety one non-redundant 
genes were differentially upregulated at 1 day, 6 weeks, and 6 months of age in the celiac 
bifurcation of the WC pigeon. When considering the placement of genes that were 
differentially upregulated at each of the three ages, previous research demonstrates that 
initiation occurs early on. In fact, Santerre reported that in the WC pigeon, spontaneous 
atherosclerosis occurs as early as 1 day (80). Therefore, genes that were differentially 
upregulated at 1 day were considered to participate in initiation of atherosclerosis. 
While the actual point at which initiation occurs is less defined, by 6weeks of age 
the biochemical and morphological hallmarks demonstrate that progression of the disease is 
well under way (57). In addition, reports suggest that factors responsible for initiation are 
independent of those that are responsible for progression (81). With that said, the initiating 
event in the WC sets in motion the documented cellular, biochemical, and molecular 
changes that ensue marking the disease progression (50). Based on these studies, genes 
that were differentially upregulated at 6 weeks and 6 months of age were considered more 
likely to participate in the progression of atherosclerosis. 
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Only a subset of the genes most likely to be involved in the disease, that were 
upregulated exclusively and annotated in MetaCore, were chosen from each of the three 
age groups to be analyzed further for their potential role in initiation and progression of 
atherosclerosis. It is important, not to lose sight of the fact that many of the genes of 
interest may actually be involved in normal development. In light of this, efforts were 
made to distinguish between genes involved in normal healthy development and those 
involved in the pathogenic state. 
Of the 7 genes that were differentially upregulated exclusively at 1 day, only 3 
genes were fully annotated in MetaCore and include, SEC61G, FKBP9, and DCN. 
According to MetaCore, SEC61G is the central component of the protein translocation 
apparatus which is necessary for translocation of proteins in the endoplasmic reticulum 
(82). FKBP9 associates with ryanodine receptor (RYR-2) in cardiac smooth muscle 
sarcoplasmic reticulum and may play a unique role in excitation contraction coupling in 
cardiac muscle. FKBP9 also has the potential to contribute to the immunosuppressive and 
toxic effects of FK506 (an immunosuppressive drug) and rapamyacin (an 
immunosuppressant) (82, 83). In a study conducted to explore novel genetic causes of 
inherited cardiomyopathies in one kindred (4 generations, 32 individuals), linkage was 
established to a novel locus on chromosome 7 (7pl2.1-7q21) which included the candidate 
genes SEC61G and FKBP9, although no disease causing mutations were identified (84). 
The third gene fully annotated in MetaCore, DCN, is recognized as bone 
proteoglycan II (82). DCN is a component of connective tissue and binds to type I collagen 
fibrils (COL1A2). The gene COL1A2 which codes for Type I collagen fibrils was also 
differentially upregulated at 1 day when compared to 6 weeks and again when compared to 
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6 months, and is also known to play a role in matrix assembly (82). DCN is also capable of 
suppressing the growth of various tumor lines (82). A study, conducted to assess the 
relationship between proteoglycans and calcification of cultured bovine aortic SMCs 
revealed that there was a significant increase in DCN, peaking by 7-10 days and decreasing 
by day 14, although it remained elevated when compared to control cells (85). The 
researchers also reported that over expression of DCN enhanced the calcification of tissues 
as seen in sheets of arterial SMCs and in colocalized regions of atherosclerotic plaques in 
arteries (85). 
Immunofluorescence of human carotid artery segments, obtained from autopsy or 
from surgery, revealed that in non-atherosclerotic arteries, DCN was detected only in the 
adventitia (86). On the other hand, in arteries that contained atherosclerotic lesions, DCN 
was present primarily in the layer of the intima close to the media with less in the 
subendothelial part of the intima (86). In addition, this study found that while type I and III 
collagen in the arterial intima associates with DCN, group II secretory nonpancreatic 
phospholipase A2 (snpPLA2) binds preferentially to DCN which enhances snpPLA2 
activity, and may contribute to the pathogenesis of atherosclerosis by modifying 
lipoproteins and releasing inflammatory lipid mediators at sites of lipoprotein accumulation 
(86). While it is not known precisely whether SEC61G and FKBP9 are responsible or 
involved in initiation of atherosclerosis, research strongly implicates DCN as a major 
player in atherosclerosis, although a specific role in initiation remains unclear at the present 
time. 
At 6 weeks, 15 of the 16 genes that were exclusive to this age were annotated in 
MetaCore. Five of these included genes responsible for ribosomal production. The first 
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three, RPL3, RPL4, and RPL5, are all components of the large 60S subunit of cytoplasmic 
ribosomes while RPS6 and RPS28 belong to the small 40S subunit of cytoplasmic 
ribosomal proteins. RPL3 belongs to the L3P family of ribosomes and is suggested to 
contribute to tat-mediated transactivation by binding to RNA which then activates 
translation (82) [Appendix D]. While RPL4 belongs to the L4E family of ribosomal 
proteins (82), a study by Zengel et al., found that RPL4 regulates the SIO operon of 
Escherichia coli by inhibiting translation of the proximal gene and by stimulating 
premature termination of transcription within the SIO leader (87). According to MetaCore, 
ribosomal protein L5 belongs to the L18p family of ribosomal proteins in the cytoplasm 
(82). Ribosomal S6 belongs to the S6E family of ribosomal proteins and may be key in 
controlling cell growth and proliferation through selective translation of particular classes 
of mRNA. It is a major substrate of protein kinases in the ribosome, with subsets of five C-
terminal serine residues that are phosphorylated by different protein kinases (82). RPS28 
belongs to the S28E family of ribosomal proteins (82) [Appendices D, and K]. 
Interestingly, RPS28 and RPL3 were also differentially upregulated exclusively at 6 
weeks in the WC when compared to the SR as shown in Anderson's unpublished in-vivo 
RDA work (63) [Appendix S]. While RPL3 was upregulated differentially at 6 weeks in 
both this work and in the in-vivo work, it was also downregulated by 6 months of age in the 
WC in both bodies of work. This was also the case in Anderson's in-vitro work (which 
represents that of a compressed time-frame of approximately 2-3 years) [Appendix Q]. 
There, RPL3 was upregulated significantly in the SR when compared to the WC. These 
patterns appear to support the ultrastructural work conducted by Cooke where he found that 
92 
free ribosomes gradually decreased in the aorta of the spontaneously atherosclerotic WC as 
they developed unlike those of the SR (88). 
In support of Cooke's findings, while many different ribosomal genes were 
differentially upregulated at each of the three ages throughout the three comparisons, most 
of the ribosomal genes that were upregulated at 6 weeks in this study were down by 6 
months of age in the WC. More specifically, 10 different ribosomal genes were 
upregulated at 6 weeks of age when compared to 1 day [Appendix D], and 8 different 
ribosomal genes were upregulated at 6 weeks when compared to 6 months in the WC. 
However, in the reciprocal age comparisons, there was no increased regulation of 
ribosomal genes at 1 day or at 6 months when compared to 6 weeks. It was suggested by 
Anderson that, although the changes in regulation could not be explained, it is possible that 
the WC is attempting to compensate for ribosomal degradation by increasing synthesis by 6 
weeks, followed by sharp a decline as the WC ages (63). This seems reasonable, given that 
this was the case in this current work and was also reported by Cooke, although future 
work will be needed to discern whether the changes in regulation by 6 weeks are due to the 
disease progression or other mechanisms that are unrelated to the disease. 
Also of interest is that many of the genes that were differentially upregulated at 6 
weeks were also involved in both transcription and translation, protein folding and 
transport. EIF3H was also upregulated exclusively at 6 weeks. While the exact role of 
EIF3H was not determined it is involved in translation of proteins following transcription 
(82). It also seems reasonable to suggest that the increased regulation at 6 weeks may be 
due at least in part to some of the increased synthesis of extracellular materials that occur 
during early progression of atherosclerosis. For example, DDX5 was also upregulated 
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exclusively at this age. It is an RNA helicase that is implicated in a number of cellular 
processes involved in altering the RNA secondary structure such as translation initiation, 
nuclear, and mitochondrial splicing, as well as ribosome and spliceosome assembly (82). 
DDX5 is known to encode a dead box protein, which is an RNA-dependent ATPase, and a 
proliferation-associated nuclear antigen, that is specifically known to react with the simian 
virus 40tumor antigen, and may also be involved in pre-mRNA splicing (82). 
Inhibitor p27 Kipl (CDKN1B) is a positive regulator of cellular and developmental 
processes that impact cell cycle progression (82). It is involved in Gl-arrest and is a potent 
inhibitor of cyclin-E and cyclin-A CDK2 complexes. It is also a positive regulator of 
cyclin-D-dependant kinases such as CDK4 that is regulated by phosphorylation and 
degradation events (82). According to Lauter et al., CDKN1B is a dependant kinase 
inhibitor which serves to repress the function of cyclin-dependent kinases, necessary for 
cellular progression through Gl to S-phase of the cell cycle (89). CDKN1B expression 
has been shown to be decreased in various tumor types including colon cancer (89) and 
may explain the decreased regulation by 6 months. 
Molatore et al., also reported that CDKN1B acts as a tumor suppressor to regulate 
the suppression of Gl to S-phase by regulating the activity of cyclin E and cyclin A CDK2 
(90). In addition to its negative role in cell cycle progression, it is involved in cell 
migration, neuronal differentiation and apoptosis (90). A study by Nowel et al., found that 
CDKN1B was downregulated while p52 was upregulated in early stage fallopian tube 
carcinoma (FTC) when compared to normal fallopian tube tissues (91). 
Immunohistochemistry results revealed that the decreased protein expression of 
CDKN1B in FTCs continued as the cancer progressed (91). In addition, when SMCs are 
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bound to fibronectins and proteoglycans in atherosclerotic plaques, CDK2 inhibitors such 
as P27Kipl are downregulated to promote SMC proliferation (34). Based on these studies, 
there may actually be a relationship between the decreased regulation of CDKN1B by 6 
months of age in the WC, the progression of atherosclerosis, and the mechanisms involved 
in tumor progression although future work will be needed to fully discern this. 
Poly (ADP-ribose) polymerase or PARP14 was also exclusively upregulated at 6 
weeks of age. PARP14 is known to enhance STAT6-dependent transcription factor, while 
STAT6 acts in response to cytokine and growth factor activity (82). PARP14 responds 
immediately to DNA damage following posttranslational modification of histones and 
other nuclear proteins in order to collectively contribute to the survival of injured 
proliferating cells (82). Research by Agarwal et al., demonstrated the enzymatic DNA 
repair activity of PARP14 in male germ cells, during spermatogenesis (92). There, 
increased levels of PARP14 were present in mature spermatozoa, in response to strand 
breaks in DNA as a result of oxidative stress, chromatin remodeling and cell death (92). 
This response of PARP14 to DNA damage was associated particularly with inflammatory 
cytokines, and with oxidative stress that was connected with protein modification due to 
biological or chemical stressors (92). During atherosclerosis, cytokine production is 
dramatically increased. Cells such as T-cells, macrophages, endothelial cells, and SMCs in 
particular, produce such cytokines as platelet derived growth factor, macrophage inhibitory 
factor (MIF+), interferon gamma (IFNy) and monocyte chemoattractant protein (MCP-1) 
(34). It is therefore possible that, the increase in PARP14 by 6 weeks of age, may be in 
response to an increase in cytokine production known to occur during atherosclerosis. 
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Ring finger protein (RNF11) contains a RJNG-H2 finger motif and a PY motif, 
which is known to be important for protein-protein interactions (82). RNF11 has been 
shown to be induced by mutant rearranged transformation (RET) proteins, also known as 
multiple endocrine neoplasia (MEN2A/MEN2B). The germline mutations in the RET gene 
are known to be responsible for the development of multiple endocrine neoplasias (82). 
Immunohistochemical analysis of RNF11 protein revealed that RNF11 was markedly 
overexpressed in breast cancer, and to a lesser extent in pancreatic and prostate cancers 
(93). It is believed that RNF11 may function as an adaptor molecule for the recruitment of 
specific substrates to E3 ligase complexes for ubiquitination and subsequent degradation by 
26S-proteosome (93). Li et al., concluded that RNF11 is likely involved in multiple cancer 
related cellular processes such as gene transcription, protein ubiquitination and 
ubiquitination associated events related to receptor endocytosis and protein sorting (93). 
Gelsolin (GSN) is a calcium-regulated, actin-modulating protein that binds to the 
plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-
blocking or capping). It can promote the assembly of monomers into filaments as well as 
sever filaments already formed (82). Nishio et al., found that gelsolin has multiple 
regulatory activities, including cytoskeletal remodeling and ion channel regulation (94). 
They also found that GSN mRNA levels are elevated while plasma concentration levels of 
GSN are decreased in patients with ischemic heart disease and in animal models of heart 
failure. As a result, they suggested that GSN plays a key role in cardiac remodeling (94). 
Work conducted by Li et al., suggests a link between GSN and induction of apoptosis 
following MI (95). They detected enhanced expression of gelsolin in human heart failure, 
and in dilated and ischemic cardiomyopathy (95). Li et al., also found that cells with 
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gelsolin are likely to produce more actin-barbed ends and actin monomers, which bind to 
deoxyribonuclease (DNase I), a key enzyme responsible for DNA degradation following 
the stimulus generated by MI, which tries to attenuate enhanced activation of promoting 
cell death by apoptosis (95). Following microarray gene expression analysis of 22,283 
human genes, it was found that GSN was markedly increased in human heart failure of 
both dilated and ischemic cardiomyopathy phenotypes (95). Immunoblotting revealed that 
GSN protein was also increased following MI in mouse models (95). In mice, COL1 Al 
and COL3A1 were also higher in GSN +/+ hearts than GSN-/- hearts which is believed to 
be pro-apoptotic(95). This relationship was not the case however, for Gelsolin at 6 weeks 
in that COL1 Al and COL3A1 were down by this age in the WC, possibly suggesting loss 
of regulation of apoptosis. Also, GSN, which is a substrate of caspase-3, -7+ -9 is 
frequently downregulated in human cancers, that are able to escape apoptosis (95). 
Caspase-3 is considered a key mediator of apoptosis in mammalian cells (96). In cells that 
were exposed to Fas receptor, there was an increased presence of GSN cleaved fragments 
through caspase-3 which then led to apoptosis of the cells (96). 
Chaperonin containing TCP1, subunit 8 (CCT8) according to MetaCore is a 
cytosolic chaperone protein that assists in protein folding upon ATP hydrolysis (82). In-
vitro it was shown to be involved in the folding of tubulin and actin, which interestingly 
ACTB was also upregulated at this age (82). The presence of CCT8 at 6weeks of age may 
actually be in response to the increased regulation of the many non-redundant genes that 
were presented in Table 9 of the results. CCT8 may also be associated with the folding of 
Vimentin (VIM), which was also exclusively upregulated at this age. According to 
MetaCore, VIM, like actins and microtubules, are class III intermediate cytoskeletal 
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filaments, which are all associated with one another in various capacities (82) [Appendices 
B and L]. VIM is found primarily in mesenchymal cells, displaying tissue specific patterns 
of expression associated with cell integrity (97). Unlike actins and microtubules however, 
VIM provides resiliency to cells during times of mechanical stress. (97). 
In a study by Goldman et al, Vim-free cells were shown to be more fragile, pointing 
to the structural role that VIM plays (97). It appears that VIM in an attempt to deal with 
stress inducing alterations associated with disease progression, is attempting to offset the 
morphological alterations that are observed in the cytoskeleton (98). As noted in the 
literature, these changes are thought to be in response to the shift in SMCs to the synthetic 
state, which is also known to increase the proliferative index of ECM, further 
compromising the integrity of atherosclerotic tissue (34). These changes were followed by 
increases in Chondroitin 6-sulfate and Chondroitin 4-sulfate, both glycosaminoglycans 
(GAG) that remain elevated at 6months. This is believed to precede and be at least 
partially responsible for the uptake of lipid in the cells, and further progression of 
atherosclerosis (16, 34). Each of these findings are believed to facilitate lipid accumulation 
and hypoxic stress, both contributors to the disease progression (16, 57). Given all that is 
in transition during this stage, it seems reasonable to suggest that the increased regulation 
observed by all these genes at 6 weeks, occurs in response, at least in part to some of the 
regulatory changes and stressors placed on aortic tissues during early progression. 
Tropomyosin (TPM1) was also exclusively upregulated at 6weeks. It functions in 
both muscle and non-muscle cells and is a member of the tropomyosin family of highly 
conserved actin binding proteins(82) [Appendices B and C]. TPM, which is regulated by 
caldesmon binds to and stabilizes cytoskeletal actin filaments during SMC contraction (82). 
98 
Rong reported a decrease in both TPMl as well as ACTA following cholesterol loading in 
SMCs, which he reported to be the result of a shift from the healthy contractile state to the 
synthetic state (39). It is well established that ACTA levels as well as other SMC 
differentiation markers, decrease in-vivo in response to atherosclerosis and or vascular 
injury (36, 99). Work conducted by Kashiqada et al., reported that a shift from 
differentiated SMCs, to dedifferentiated SMCs led to the phenotypic modulation of TPMl 
causing it to shift from a SMC type to a fibroblastic type 1 and 2 (100). 
A shift in regulation between ACTA and ACTB was observed at 6weeks in this 
current research. Here ACTA was up at lday and again by 6months, while ACTB was not 
upregulated until 6weeks and remained up at 6months. Interestingly, Anderson found an 
inverse relationship between ACTA and ACTB (63). The results from her work suggest 
that higher levels of ACTA represent normal contractility, while increased regulation of 
ACTB represents a loss of contractility in the SMC (63). She proposed that decreased 
ACTA and TPMl, in parallel with increased ACTB, signal a loss of muscle contraction 
(63). 
It is possible that the upregulation of TPMl at 6weeks in the current results had not 
yet caught up with the changes in regulation between ACTA and ACTB. The increased 
regulation that was observed by TPMl exclusively at 6weeks may actually reflect a 
compensatory mechanism of the WC, to at least initially maintain some sort of regulation 
during the transition from the contractile state to the synthetic state (100). 
Spermidine/spermine Nl-acetyltransferase (SAT1) was also upregulated 
exclusively at 6weeks and is a member of the family of sulfate/anion transporters. 
According to MetaCore, SAT1 functions as a sodium-dependent amino acid transporter, 
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which participates in many reactions such as the uptake of nutrients, detoxification, energy 
production, and neurotransmitter cycling (82) [Appendices M and N]. In multiple studies, 
SATl was upregulated during times of stress. Babbar reported that, increases in the 
cytokine, tumor necrosis factor alpha (TNFalpha), resulted in increases in SATl which 
encodes a rate-limiting polyamine catabolic enzyme, reducing intracellular polyamine 
contents in lung cancer cells (101). SATl has also been associated with decreased cell 
growth and apoptosis (101). A study by Wang et al showed that, over expression of SATl 
resulted in rounding up and loss of cell anchoring, along with alterations in the morphology 
of actin-containing filopodia (102). In another study SAT2, not SATl, was shown to have 
a high affinity for I-proline transport in vascular SMCs while SATl was found exclusively 
in brain cells (103). These findings conflict with Babbar's work, as well as the results of 
this current research, and Anderson's work, which all found that SATl was upregulated in 
the WC when compared to the SR. Perhaps the increased cytokine production in response 
to disease progression of atherosclerosis, as reported by Doran, may explain the increased 
regulation of SATl at 6 weeks. 
While it is interesting that many of the genes that were upregulated at 1 day and at 6 
weeks were associated with transcription, translation and changes in cell integrity, a 
number of the genes were also associated with decreased immune function, increases in 
cytokine production, inflamation, and progression of some tumor lines and cancers. It is 
also interesting that 6 of the genes that were differentially upregulated in the WC, were 
reportedly expressed in multiple tumor lines and cancers. While it is not known at this 
point, whether this is due to the large amount of work that has been conducted on tumors 
and cancers, this pattern does seem to raise interest in Benditt's monoclonal theory of 
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atherogenesis (104). It is also possible that the increased regulation at 6 weeks was an 
early compensatory mechanism to control some of the negative downstream affects 
following initiation and even early progression, especially those in response to stress and 
cytokine production. It is also important to note that 6 of the 15 genes that were 
upregulated exclusively in the WC and analyzed here, were also upregulated in the WC 
when compared to the SR in Anderson's unpublished in-vivo work. Those genes include 
CCT8, VIM, TPM1, RPL3, RPS28, and SAT1, which are presented in Appendix A. 
Future work will be needed to fully understand the mechanisms, in which these genes are 
involved. 
At 6 months of age, genes that were differentially upregulated exclusively include 
ENOl and ACSLl. The first gene, ENOl is a multifunctional enzyme that participates in 
the later steps of glycolysis to convert 2-phosphoglycerate to phosphorenolpyruvate (82) 
[Appendices E, F and J]. It is also known to participate in many additional metabolic 
functions such as the regulation of growth, response to hypoxic conditions, and 
immunoglobulin production (82). Unpublished in-vitro SMC work conducted previously 
in this lab revealed that ENOl was differentially upregulated (30:0) in the WC when 
compared to the SR (63) [Appendix Q]. Additional in-vivo work revealed however, that 
ENOl was not differentially upregulated at 6months when compared to the SR [Appendix 
T]. This appeared to confound ENOl as a major gene of interest in the progression of 
atherosclerosis, although it is quite possible that this type of regulation of ENOl in-vitro 
indicates that ENOl is acting at the level of the SMC. Since this was in-vitro, it may also 
indicate that the increased regulation of ENOl occurs much later than 6months of age. 
Research shows that SMCs have been shown to be the first cells present in locations 
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destined to develop atherosclerotic plaques (34, 39, 105), and that intrinsic properties of 
SMCs are intimately implicated with the regulation of the disease (49). Since ENOl was 
also associated with hypoxic stress according to MetaCore, and given that one of the 
characteristics of atherosclerosis is that of hypoxic stress, coupled with the role of SMCs, 
ENOl appears to remain a primary gene of interest involved in atherosclerotic progression. 
In regards to energy production, Hajjar et al showed that the WC totally lacked ATP 
regulation of NADH transhydrogenation by 6weeks of age, and by 6months had lower P/O 
ratios as compared to the SR, suggesting uncoupled respiratory-chain phosphorylation (17), 
which may in part explain the increased regulation of ENOl. While examining the 
differences in energy production between both breeds, Zemplenyi revealed there were 
differences in the amount of arterial enzymes that were produced between WC and SR 
pigeons at 5-8 weeks of age. His findings demonstrated that there was in fact a clear shift 
in the WC from oxidative phosphorylation to glycolysis at the level of the arterial wall 
(106). Zemplenyi suggested that this hypoxic shift predisposed the WC to atherosclerosis. 
He also found that lipoamide dehydrogenase, a component of the pyruvate dehydrogenase 
complex was significantly lower in the WC when compared to the SR (106). The 
decreased amount of lipoamide dehydrogenase in the presence of acetyl CoA slowed down 
the conversion of pyruvate to oxaloacetate markedly slowing down the ICrebs cycle. There 
was also an increase in the amount of phosphofructose kinase, which is the rate-limiting 
step of glycolysis in the WC at this age. This effect was however believed to be a 
secondary effect resulting from the decreased rate of the Krebs cycle (106). 
Work conducted by Santerre found that respiratory control ratios in the WC were 
high at lday, dropping to low levels by 3-6 months unlike the SR, where respiratory ratios 
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increase as the SR grows and develops (80). Zemplenyi also found that tissue hypoxia not 
only forces glycolysis to become the primary energy pathway but it also contributes to the 
accumulation of lipids and the synthesis of arterial connective tissue apparatus (106). 
Hajjar et al showed that tissue hypoxia occurs later, following a rise in GAGs (64). By 12-
24 weeks, they were able to demonstrate that the 02 tension in the medial layer of WC was 
lower than that in the SR and in younger WC pigeons (64). By 6 months, increases in 
chondroitin 6-sulfate and other GAGs were present which have been correlated with lipid 
accumulation (16). 
As stated previously, acyl-CoA synthetase long-chain family member 1 (ACSL1) 
was also differentially upregulated exclusively by 6months. ACSLls are membrane bound 
long chain synthetases that trap fatty acids on the cytosolic side following passive diffusion 
across the plasma membrane (107) [Appendices G and I]. This timing of the increased 
regulation of ACSL1, according to MetaCore, occurs in response to an increase in the 
synthesis of lipids, and appears to correlate well with the build up of lipids observed by 
Zemplenyi, and the rise in GAGs reported by Hajjar et al. Increases in ACSL1 are also 
known to occur in response to beta-oxidation of fatty acids, which must first be converted 
to fatty acyl-CoA in the cytosol using ACSL1 [Appendix H]. These are then transported 
into the mitochondria assisted by the carnitine shuttle to then undergo beta-oxidation to 
their two carbon units. Un-published in-vitro work in this lab revealed that ACSL1 was 
also differentially upregulated when compared to the SR, which correlates well with the 
energy changes that occur as a result of the disease progression. This loss of regulation in 
energy metabolism represents a shift from oxidative phosphorylation to glycolysis as the 
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dominant energy pathway by 6 months in the WC, and that it may actually be at the level of 
the SMC. 
Limitations 
While the RDA method is quite effective at presenting only genes that are 
differentially expressed between two similar populations, limitations do exist within the 
context of this project. Given the narrow selection process of analyzing only genes 
differentially upregulated exclusively at 1 day, a number of potential genes of interest were 
excluded, reducing the chances of finding a gene responsible for initiation. 
Such a small amount of starting material that was used from the original pool of 
cDNA at the onset of RDA, may also have limited the selection process of potential genes 
throughout, especially since only lng was used during the third rounds of SH. While the 
goal of the RDA method was to remove genes common between both populations, it was 
observed following Rounds 3, that electrophoresis gels revealed some of the bands were 
less defined than in the previous round. As a result, questions were raised whether actual 
quality difference products were removed, therefore reducing potential genes of interest at 
all of the ages. The small amount of cDNA that was used originally could further reduce 
the chances of finding a gene of interest. The other point to keep in mind is that, the 
amount of total RNA that was collected prior to RDA represents only a snapshot in time. 
Despite these limitations, the level of sensitivity of the RDA method is impressive in that it 
can select for genes differentially upregulated, of low copy number and then amplify them, 
without prior knowledge of their sequence, and with a low number of false positives (72). 
In addition, of the 286 quality sequences that were unidentified, 68% were 
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upregulated at 1 day alone [Appendices O and P]. This fact alone makes it likely that the 
gene(s) associated with initiation remain unknown. Given the RDA method, the 
parameters of selection, and the large number of unidentified genes that remain, it is quite 
probable that additional gene(s) of interest associated with initiation and progression 
remain elusive. 
Future work that encompasses a wider scope of analysis, and includes more 
complex and detailed investigation of additional candidate genes may be helpful in 
identifying genes responsible for atherosclerosis. Additional research is also needed to 
identify the 196 unidentified quality ESTs that were upregulated at 1 day. It is also quite 
possible that the gene (s) of interest lie in this group of ESTs. Given all these limitations, 
and in light of the technology that is currently available, the RDA method is still the best 
method we have at this point in time. 
When considering the genes that were not placed in either initiation or progression, 
new research demonstrates that genes share dual roles. It is also possible that the two 
processes of initiation and progression, may not be distinct from one another (or at least for 
some of the genes) as reported by Herndon et al. Some of the genes that were differentially 
upregulated at 1 day, and again at 6 months may actually share this duality. For example, 
genes that were differentially upregulated at 1 day may reflect initiation, yet when they 
were differentially upregulated at 6 months, they may in fact reflect normal development, 
or progression of the disease. According to Seroude, changes in gene regulation are 
associated with the rate of physiological aging as opposed to chronological aging (108). 
Interestingly, aging is associated with the same highly dynamic regulatory changes 
observed during development, and these same regulatory changes that occur during aging, 
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also occur in response to stress (108). In fact, both the up and downregulation of genes 
whose expression changed during aging, also changed when exposed to oxidative stress 
(109). All told, it is the combination of genes and their regulation that impacts the 
downstream effects (108). In light of this and the current findings, future work will be 




A number of candidate genes were differentially upregulated at 1 day. More 
importantly seven genes were differentially upregulated exclusively at 1 day, therefore 
placing them as potentially being involved in initiation of atherosclerosis in the WC pigeon 
under the conditions evaluated in the hypothesis. However, given the tight parameters of 
this hypothesis, while SEC61G, FKBP9 and DCN were correlated with atherosclerosis they 
could not be definitively assigned a significant role in initiation. 
At 6 weeks and at 6 months, seventeen candidate genes were differentially 
upregulated exclusively, and were analyzed for their role with progression of 
atherosclerosis. The genes included RPL3, RPL4, RPL5, RPS6, RPS28, EIF3H, DDX5, 
CDKN1B, PARP14, RNF11, GSN, CCT8, VIM, TPM1, SAT1, ENOl, and ACSL1. The 
events associated with these genes include increases in ribosomal biogenesis in response to 
increased protein synthesis, transcription, translation, splicing associated with transcription 
and translation, regulation of cell cycle progression, immune and inflammatory functions, 
stress associated with protein translation and modification. Several genes were also 
involved in ubiquitination and degradation, cytoskeletal remodeling and apoptosis, 
increases in chaperonin protein involved in the folding of newly translated proteins, 
decreases in cellular integrity, changes in muscle contraction, and increases in a transporter 
gene that was also upregulated in response to cellular stress, and increased regulation of 
cell cycle. 
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Finally, changes in energy metabolism were apparent by 6 months of age reflecting 
a shift from oxidative phosphorylation to glycolysis in the WC pigeon, as well as increases 
in lipid synthesis and degradation. These findings concur with previous studies which 
strongly suggest that this energy shift is a major event in the development of 
atherosclerosis in the WC pigeon. 
Future work will be necessary to fully analyze the functional role for each of the 
major candidate genes associated with initiation and progression of atherosclerosis, as well 
as for the many additional genes of interest that were not analyzed based on the current 
hypothesis. Also, many more unidentified quality transcripts were differentially 
upregulated at 1 day than at any other age according to the e- value criteria of acceptance. 
It will therefore be essential to identify and further annotate the quality sequences that were 
retained so that they can then be analyzed for their potential role in initiation of 
atherosclerosis. 
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APPENDIX A: GENE FUNCTION ACCORDING TO METACORE 
Table 1: Genes Upregulated or Downregulated Exclusively in WC and in WC When 
Compared to SR 
Genes Upregulated or Downregulated exclusively in the WC in this Current Body of Work and in Anderson's Work 


























Ribosomal Protein L3 
Ribosomal Protein S28 
Chaperonin Cbntaininq TCP1, subunit 8 
Vimentin 
Tropomyosin, Alpha 
Spermadine/Spermine N1-Acetyltransferase variant 1-like 
Enolase, Alpha 
Acvl CoA Synthetase Long Chain Family Member 1 
Eukaryotic Translation Initiation Factor 1 
Ribosomal Protein S3A 
Function(s) 
The L3 protein is a member of the larges 60S subunit of cytoplasmic ribosomes 
responsible for catalyzinq protein synthesis. 
The S28 is a component of the small 40S subunit of cytoplasmic ribosomes 
responsible for catalyzinq protein synthesis. 
Assists in the folding of proteins upon ATP hydrolysis. Known to play a role, in-
vitro, in thefoldinq of actin and tubulin 
Are class II intermediate filaments found in various non-epithelial cells, 
especially mesenchymal cells. Along w/ actins and tubulins, it represents a 
third class of well characterized cytoskeletal elements 
Binds to actin filaments in both muscle and non-muslce cells. Plays a role, in 
association with the troponin complex. In the calcium dependent regulation of 
vertebrate striated muscle contraction. In SMC contraction is regulated by 
interaction with caldesmon. In non-muscle cells is implicated in stabilizing 
cytoskeleton actin filaments. 
Is a member of a family of slfate/anion transporter genes. Functions as a 
sodium-dependent amino acid transporter. Plays an essential role in the 
uptake of nutrients, production of energy, chemical metabolism, detoxification, 
and neurotrnsmitter cycling. 
Multifunctional enzyme, that in addtion to its role in glycolysis, participates in 
regulation of growth, hypoxic conditions, and immunity. Has the ability to serve 
as a receptor and activator of plasminogen on the cell surfaces of such cell-
types as leukocytes and neurons. Stimulates immunoglobulin production. 
Is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Converts 
free long-chain fatty acids into fatty acyl-CoA esters, and thereby plays a key 
role-in lipid biosynthesis and fatty acid deqredation. 
Is necessary for scanning and is involved in initiation site selection. Promotes 
the assembly of 48S ribosomal complexes at the authentic initiation codon of a 
conventional capped mRNA 
The S3A protein is a member of the small 40S subunit located in the cytoplasm 
responsible for protein synthesis 
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APPENDIX B: METABOLIC PATHWAY - VIM & TPMl 
Figure B.l: C-1 (lday-red versus 6weeks-blue) 
VIM & TPMl Upregulated at 6weeks 
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APPENDIX C: METABOLIC PATHWAY - TPMl 
Figure C.2: C-1 (lday-red versus 6weeks-blue) 
TPMl upregulated at 6weeks 
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APPENDIX D: METABOLIC PATHWAY - RPL3 & RPS28 
Figure D.3: C-1: (lday-red versus 6weeks-blue) 
RPL3 & RPS28 Upregulated at 6weeks 
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APPENDIX E: METABOLIC PATHWAY - ENOl 
Figure E.4: C-2: (1 day-red versus 6months-blue) 
ENOl Upregulated at 6months 
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APPENDIX F: METABOLIC PATHWAY - ENOl 
Figure F.5: C-2: (1 day-red versus 6months-blue) 
ENOl Upregulated at 6months 
Glycolysis 
:*•/.. i f 
« 
\ 





























APPENDIX G: METABOLIC PATHWAY - ACSLl 
Figure G.6: C-2: (lday-red versus 6months-blue) 
ACSLl Upregulated at 6months 
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APPENDIX H: METABOLIC PATHWAY - ACSLl 
Figure H.7: C-2: (lday-red versus 6months-blue) 
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APPENDIX I: METABOLIC PATHWAY - ACSLl 
Figure 1.8: C-2: (lday-red versus 6months-blue) 
ACSLl Upregulated at 6months 
Regulation of Lipid Metabolism 
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APPENDIX J: METABOLIC PATHWAY - ENOl 
Figure J.9: C-3 (6weeks-red versus 6months-blue) 
ENOl Upregulated at 6months 
Transcription Role of Akt in Hypoxia Induced HIFl Activation 
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APPENDIX K: METABOLIC PATHWAY - RPL3, RPS28, 
Figure K.10: C-3 (6weeks-red versus 6months-blue) 
RPL3, RPS28, Upregulated at 6weeks 
Translation-Regulation of Translation Initiation 
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APPENDIX L: METABOLIC PATHWAY - VIM 
Figure L . l l : C-3 (6weeks-red versus 6months-blue) 
VIM Upregulated at 6weeks 
Development-Wingless-Type MMTV Integration Site Family (WNT) Signaling 
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APPENDIX M: METABOLIC PATHWAY - SATl 
Figure M. 12: C-3: (6weeks-red versus 6months-blue) 
SATl (SSAT) Upregulated at 6weeks 
Gamma-aminobutyrate (GABA) Biosynthesis and Metabolism 
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APPENDIX N: METABOLIC PATHWAY - SATl 
Figure N.13: C-3: (6weeks-red versus 6months-blue) 
SATl (SSAT) Upregulated at 6weeks 
Polyamine Metabolism 
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APPENDIX O: Table 2: C-l Unidentified Transcripts lday versus 6weeks 
Comparison 
Age 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1DayA 
C 1 1DayA 
C 1 1 Day A 
C 1 1DayA 
C 1 1DayA 
C 1 1DayA 
C 1 "IDayA 
C 1 IDayA 
C 1 IDayA 
















































































APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued) 
C o m p a r i s o n 
Ass® 
C 1 1 D a y A 
C 1 I D a v A 
C 1 1Day A 
C 1 1Day A 
C 1 1 Day A 
C 1 1 D a y A 
C 1 I D a v A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 Day A 
C 1 1 D a y A 
C 1 1 Day A 
'ZW'.' 
C 0 9 
C 1 1 
D 0 1 
D 0 4 
D10b 
E01b 
E 0 3 
E07a 
E07b 
E 0 8 
E 1 0 
F 0 3 
F 0 6 
F I O 
G 0 7 
G 0 8 
®iK® <#&|3) 
3 2 3 
5 5 5 
3 2 3 
3 2 3 
3 2 3 
2 4 3 
3 2 3 
2 2 7 
1 4 7 
3 2 7 
3 2 3 
3 2 3 
4 3 3 
2 3 
3 2 3 
2 3 7 
S e q u e n c e s 
G A T C C T T G G A G G T C A T A T A T A A A C A G G T A T A T C T - A C C T A T C T A T C C A T T T G T C T A T A G A C A T A G A T A T G G A T A G A G A T A C A G G T A T A T T T C T T T C C A T T A G G T 
C C C A G C T G T G G T A T A G A A C A C A T T C G C T C T G A G A G G T T T C C T C T T T C A G A G T T C C A T G G T A T T T C G C A G T G T T G G T A G G G G A T G G C A T A T G A A G T C T A A T T 
T T G C T G T C C A C G A A G C T C T C A T A G T G T C C A A C T T T C T C A C T C C T G C A A A A G T T A T G T T A A A C C T C C C A T G A T T T T C A C T A A T C C A A C T C A T C T C G A A T T T A G A 
A G C A A A C A A A C T G A T C 
G A T C T A T T C A C C T G C T G T T C T G C T G C T C C A C C T G C C C C G T C G C C T C A C T A C C T G G T C C A G C C G T T C A G C T G G G A T G A C T C A T C T C T G C A C G A G T A C A T T G T 
T A A A T G A T G T A T T T T C A G G G G T T T G T T T C T G C A A A A G C A G A A G G A A G G A T A A A G A C C T T T C C T T A A T A C C A C A T C A C T T A C T T T G T T T G C C T C C C T C C T T T G C 
C T T T T T T G A A G C A G A A A A A G C A C A G T G G C T G A A T C C T T C A G G C T T C T G A A T G C C A G G C T A A T G T G C A A T T C C C C G C T T C G T A A T G A A A G G C A T C A T A A G T C A 
A G G G C A T C T G C A T C A T C C T C C C C C A G A T A A C A G T T T A C T G A A G C A G T G A A A G G G A A A G A G C T T T C A A A G T T T G T T G C A A A A A T T T C A G A T C T T A G C C A C T G G 
A A T A C A G G C A C A A A C T T C C C T T T A T G T G T G A C C T T G C T G G G T G C C A G C T G G T A T A C T A T C A G A T G C T A T T T A A A A A A G A A A C A A A C A A A C A A A A A C A A A G C C 
A T G G C T T T T T T T T C C C A C C T G A G A C C A T T G T C T T T G A A G T T G A T C 
G A T C C T T G G A G G T C A T A T A T A A A C A G A T A T A T C T A C C T A T C T A T C C A T T T G T C T A T A G A C A T A G A T A T G G A T A G A G A T A C A G A T A T A T T T C T T T C C A T T A G G T C 
C C A G C C G T G G T A T A G A A C A C A T C C G C T C T G A G T G G C T T C C T C T T T C A G A G T T C C A T G G T A A T T C G C A G T G T T G G T A G G G G A T G G C A T A T G A G G T C T A A T T T 
T G C T G T C C A T G A A G C C C T C A T A G T G T C C A A C T T T C T C A C T C C T G C G A A A G T T A T G T T A A A C C T C C C A T G A T T T T C A C T A A T C C A A C T C A T C T C G A A T T C A G A A 
G C A A A C A A A C T G A T C 
G A T C C T T G G A G G T C A T A T A T A A A C A G A T A T A T C T A C C T A T C T A T C C A T T T G T C T A T A G A C A T A G A T A T G G A T A G A G A T A C A G A T A T A T T T C C T T C C A T T A G G T C 
C C A G C T G T G G T A T A G A A C A C A T T C G C T C T G A G A G G C T T C C C C T T T C A G A G T T C C A T G G T A T T T C G C A G T G T T G G T A C G G G A T G G C A T A T G A A G T C T A A T T T 
T G C C G T C C A T G A A G C T C T C A T A G T G T C C A A C T T T C T C A C T C C T G C A A A A G T T A T G T T A A A C C T C C C A T G A T T T T C A C T A A T C C A A C T C A C C T C G A A T T C A G A A 
G C A A T C A A A C T G A T C 
G A T C A G T T T G T T T G C T T C T G A A T T C G A G G T G A G T T G G A T T A G T G A A A A T C A T G G G A G G T T T A A C A T A A C T T T T G C A G G A G T G A G A A A G T T G G A C A C T A T G A G 
A G C T T C A T G G A C A G C A A A A T T A G A C T T C A T A T G C C A T C C C C T A C C A A C A C T G C G A A A T A C C A T G G A A C T C T G A A A G A G G A A G C C T C T C A G A G C G A A A G T G T 
T C T A T A C C A C A G C T G G G A C C T A A T G G A A A G A A A T A T A T C T G T A T C T C T A T C C A T A T C T A T G T C T A T A G A C A A A T G G A T A G A T A G G T A G A T A T A T C T G T T T A T A T 
A T G A C C T C C A A G G A T C 
G A T C A A C A A C T A G T T G C T T A T C C A G G T T T C A G T C T C C A C A G C A G A G T T T T G C T T T C T C C T T T A T T T G T G C A C T A G A A A G T G A A G T T G T T T T C T T C C C C T G C T T 
C C T C C A A G A A G A A G A A T G G A A G G C A A A T A A A T A G T A G A G A A T A C A G C C A T C A A G T T T G A G A G A T G A C C T T T A C A C T T C T A T G G C A T T T G C A A C C T A C A A C C T 
T G C C T T C C C C A C T T C C A C T G G C T A C A G C T A A C A T G A T C 
G A T C A G T T T G T T T G C T T C T G A G T T C G A G A T G A G T T G G A T T A G T G A A A A T C A T G G G A G A T T T A A C A T A A C T T T T G C A G G A G T G A G A A A A T T G G A C A C T A T G A G 
A G C T T C A T G G A C A G C A A A A T T A G A C T T C A T A T G C C A T C C C C T A C C A A C A C T G C G A A A T A C C A T G G A A C T C T G A A A G A G G A A G C C T C T C A G A G C A A A T G T G T 
T C T G T A C C A C A G C T G G G A C C T A A T G G A A A G A A A T A T A T C T G T A T C T C T A T C C A T A T C T A T G T C T A T A G A C A A A T G G A T A G A T A G G T A G A T A T A T C T G T T T A T A 
T A T G A C C T C C A A G G A T C 
G A T C T T C A C C A T A C C T T G A T A T T T C A T T C T T G G G A C T A G G C T G A T A G A T G A T T T C A A C T G C T C T G A C A G G G C C A T G C T A G A T G T A T C T G T G C T C T C T A C C T G 
A A G C A C A C A C T C G G G G G A T G C T T C C A A T T T T C T C T G T T T A T T G T G G A T T T G C A A G G A T A A A C A A G G A C A C T G A C C G C T T C C C C G G G G G T G C A G G A A T C T T T 
A A A G C C C T G T A A G A A T A C C G C A A C A A C T C A A T A G G G G G C C C G G C A T C C A C C T T G C C C T A T G G G G A G T C G T A T T A C T T G C T G A G T G C G G G C G T C G T T T T G A 
G G C C T G C A G A G G G G A A A A A G C C T G G G G C T A C C C A A A T G G T G G C C C T T T A A G T A C A C C C C C C A T T C A C C C A G T G G C T C A A T C A C G A A G A C G G C C T C C T T A 
C T C A A A C A T T T A T A C A G T T G T G C C A C C T G A A T G G C C A G T T C C A C A C T C C C T G A A G G G G C A A G A T A T C T C A T C C C C G G G G T G G G T T A C A T T C A A T A T C A A C G 
C T A C G A T G C C A G C G C C C T C G A G G G G G G G T C C T G T A C C C A 
G A T C T T C A C C A T A C C T T G A T A T T T C A T T C T T G G G A C T A G G C T G A T A G A T G A T T T C A A C T G C T C T G A C A G G G C C A T G C T A G A T G T A T C T G T G C T C T C T A C C T G 
A A G C A C A C A C T C G G G G G A T G C T T C C A A T T T T C T C T G T T T A T T G T G G A T T T G C A A G G A T A A A C A A G G A C A C T G A C C G C T T C C C C G G G G G T G C A G G A A T C T T T 
A A A G C C C T G T A A G A A T A C C G C A A C 
A A G G G A G C C T T G G A G G T C A T A T A T A A A C A G A T A T A T C T A C C T A T C T A T C C A C T T G T C T A T A G A C A T A G A T A T G G A T A G A G A T A C A G A T A T A T T T C T T T C C A T T 
A G G T C C C A G C T G T G G T A T A G A A C A C A T T T G C T C T G A G G G G C T T C C T C T T T C A G A G T C C C A T G G T A T T T C G C A G T G T T G G T A G G G G A T G G C A T A T G A A G T C T 
A A T T T T G C T G T C C A T G A A G C T C T C A T A G T G T C C A A C A T T C T C A C T C C T G C A A A A G T T G T G T T A A A C C T C C C A T G A T T T T C A C T A G T C C A A C T C A T C T C G A A T G 
C A G A A G C A A A C A A A C T G A T C 
G A T C A G T T T G T T T G C T T C T G A A T T C G A G A A G A G T T G G A T T A G T G A A A A T C A T G G G A G G T T T A A C A T A A C T T T T G C A G G A G T G A G A A A G T T G G A C A C T A T G A G 
A G C T T C A T G G A C A G C A A A A T T A G A C T T C A T A T G C C A T C C C C T A C C A A C A C T G C G A A A T A C C G T G G A A C T C T G A A A G A G G A A G C C T C T C A G A G C G A A C G T G T 
T C T A T A C C A C A G C T G G G A C C T A A T G G A A A G A A A T A T A T C T G T A T C T C T A T C C A T A T C T A T G T C T A T A G A C A A A T G G A T A G A T A G G T G G A T A T A T C T G T T T A T A 
T A T G A C C T C C A A G G A T C 
G A T C A G T T T G T T T G C T T C T G A A T T C G A G A T G A G T T G G A T T A G T G A A A A T C A T G G G A G G T T T A A C A T A A C T T T T G C A G G A G T G A G A A A G T T G G A C A C T A T G A G 
A G C T T C A T G G A C A G C A A A A T T A G A C T T C A T A T G C C A T C C C C T A C C A A C A C T G C G A A A T A C C A T G G T A C T C T G A A A G T G G A A G C C T C T C A G A G C A A T T G T G T T 
C T A T A C C A C A G C T G G G A C C T A A T G G A A A G A A A T A T A T C T G T A T C T C T A C C C A A G T C T A T G T C T A T A G A C A A A T G G A T A G A T A G G T A G A T A T A T C T G T T T A T A T 
A T G A C C T C C A A G G A T C 
G A T C A G C A A A G G G C T G G G A A C T G C C C C C A G A A G T G T G C A C T G G A C T A T G G C C T T A A G T T C G C G A T G G A A G A C A A C A G A G C C A G C A C A C C C A G G T T C C T C 
T G C C A C C A T A G T G A C C C T G G G C A T C T C C A A T C T T T C T T C T G G A G A G T C A G G C T G G A C A G C A G A G C A A T A C T G T C C C A C C T T A C T T C C C A C G A T T C T T C T G G 
A C C T G G C A G C T G T G A A G T G C T C C C A T T T T C T G C A T T T T A C A T G C A C C C T G T A G A C C A A G C A G A C T G C A G T C A T T G A G G A A A T C T A T G A T A G A A A T G G G A A T 
G G G A C T G C A G G A G G C T T T C A G G T G A A T A G T T T C T A A C T A G T T G T G A A A T T C T T C A G C G G G A A G G G A A C G T G C A A G T G C T G C A G A G G C A A T A T A G C C A G C T 
T T A C A T C A T T G C C C A A G C C C A T A A C C A T G A T C 
G A T C C T T G G A G G T C G T A T A T G A A C A G A T A T A T C T A C C T A T C T A T C C A T T T G T C T A T A G A C A T A G A T A T G G A T A G A G A T A C A G A T G T A T T T C T T T C C A T T A G G T 
C C C A G C T G T G G T A T A G A A C A C A T T T G C T C T G A G A G G C T T C C T C T T T C A G A G T T C C A T G G T A T T T C G C A G T G T T G G T A G G G G A T G G C A T A T G M G T C T A A T T 
T T G C T G T C C A T G A A G C T C T C A T A G T G T C C A A C T T T C T C A C T C C T G C A A A A G T T A T G T T A A A C C T C C C A T G A T T T T C A C T A A T C C A A C T C A T C T C G A A T T C A G A 
A G C A A A C A A A C T G A T C 
G A T C C T T G G A G G T C A T A T A T A A A C A G A T A T A T C T A C C T A T C T A T C C A T T T G T C T A T A G A C A T A G A T A T G G A T G G A G A T A C A G A T A T A T T T C T T T C C A T T A G G T C 
C C A G C T G T G G T A T A G A G C A C A T T C G C T C T G A G A G G C T T C C T C T T T C A G A G T T C C A T G G T A T T T C G C A G T G T T G G T A G G G G A T G G C A T A T G A A G T C T A A T T T 
T G C T G T C C A T G A A G C T C T C A T A G T G T C C A A C T T T C T C A C A C C T G C A A A A G T T A T G T T A A A C C T C C C A T G A T T T T C A C T A A T C C A A C T C A T C T C G A A T T C A G A A 
G C A A A C A A A C T G A T C 
G A T C C A G A G G A G A G C T C A C A A A G A A C A G A T A A T G T T A G A T G A G T G T A G A T A A C A G C C T T C T T T C T T T G A C A A A A A T A C C A G T T T T C A T T T T T T A A A T G T G C C T 
A T G A A G A T A A G A A A A T G T C C A T T T T G A T C 
APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued) 
Comparison 
A g e 
C 1 1 Day A 
C 1 1 Day A 
C 1 1DavA 
C 1 IDayA 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1Day B 
C 1 1Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 




H 0 7 
H 0 8 
A 0 1 
A06b 
A 0 7 
A 0 8 
A 1 1 
B02 
B 0 3 
B 0 4 
B07b 
B 1 0 
D03b 
D 0 6 
Stsse <#bp) 
323 
3 2 0 






3 0 9 
3 2 3 
323 
246 
























































G l IA I 1 1 AA 1 AUCAGA1 G 1 1AAC1CAU1 IA IA ICAGI 1GACAAAG1U1 IUUGI 1 1 1 1 1 1 1 1 1 C 1 U 1 AAACCG 1 UCCAAAACACCA 1 IAI I A I A I IA I 1 1 1 ACCA 
AGAAATAAAGGCAGTTGTGTTCAACTGTAGGGCAATGGCCTTTTATTTTTACTTGTAGTCAGAGTTAGAAAGCTGTTACTGTTACTCACAAGGAACAAAACA 




APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued) 
Comparison 
A g e 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1Day B 
C 1 1Day B 
C 1 1 Day B 
C 1 1Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 
C 1 1 Day B 



































































































APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued) 
Comparison 
Age 
C 1 1DayB 
C 1 1 Day B 
C 1 1DayB 
C 1 1DayB 
C 1 1DayB 
C 1 1DayC 
C 1 1 Day C 
C 1 1DayC 
C 1 1DayC 
C 1 1DayC 
C 1 1DayC 
C 1 1DayC 
C 1 1 Day C 
C 1 1DayC 















































































APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued) 
Compar i son 
A g e 
C 1 1 Day C 
C 1 1DayC 
C 1 1 Day C 
C 1 1 Day C 
C 1 1DayC 
C 1 1 Day C 
C 1 1DayC 
C 1 1 Day C 
C 1 1 Day C 
C 1 1DayC 
C 1 1 Day C 
C 1 1DayC 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1DayD 





G 0 3 
G08a 
G 1 0 
G11a 
G11c 
H 0 2 
H 1 2 
A 0 3 
A 1 2 
B01 





























































UA I C I UCOA I I I C I AAGUAAAGGC I I I I I G I I GAAAI GC I I I I I G I I I G I I CAI I I G I I I CACACC I CAGC I I I I AI I I GA I C 
GATCAAGTGCTTATATTGGAAACATAAATCTACTTCCAGTCCTGTTCCTAACATATTTGTATAAATGAAGAATGCTGCATTCCAGTCTCTTGTGGCCGTATTT 
TTGGTTGTGGCCTGAAAGGCTCCTCTAAAGAGACATCAGCAGTGAATGTCAGAGAATCAGAGAGTGAAATATCCCTGGCCCGAGAAGTGCCAATGGGTTT 













APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued) 
Comparison 
Age 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1DayD 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 
C 1 1 Day D 




















































































APPENDIX P: Table 3: C-2 Unidentified Transcripts lday versus 6months 
Comparison 
A g e 
C 2 1 Day A 
C 2 1 Day A 
C 2 1Day A 
C 2 1Day A 
C 2 1Day A 
C 2 1Day A 
C 2 1 Day A 
C 2 1 Day A 
C 2 1 D a y A 
C 2 1 Day A 
C 2 1 D a y A 
C 2 1 Day A 
C 2 1Day A 
C 2 1 D a y A 
C 2 1 Day A 
C 2 1Day A 
B 0 3 




C 1 0 
C12b 
D 0 4 
D 0 5 
F 0 1 
F 0 2 
F 0 3 





3 7 9 
3 8 8 
3 1 7 
3 6 5 
2 9 2 
3 2 3 
2 5 9 
3 2 3 
3 2 3 
3 2 3 
3 2 3 
2 6 5 
3 2 2 
4 0 3 
3 6 3 
4 3 6 









TACCTCTATTGGCAGTCTCTTCTCTTTGCTGCCTCAACATTCTCATCCGTACAGCATTTATA I I I I CAAAACAAATAAAAACAAAAAAACCCTCCCTTTG 
TTTTC C C TTAAAG AAAGT 

























TAACTGTTTATATATGAC CTC CAAG GATC 
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA 
GGTCCCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTCCGCAGTGTTGGTAGGGGATGACATATGAAG 






















APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued) 
Comparison 
A g e 
C 2 1DayA 
C 2 1 Day A 
C 2 1 Day A 
C 2 1 Day A 
C 2 1DayB 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1DayB 
C 2 1 Day B 
C 2 1Day B 
GOS 
G09b 
G 1 2 
H 0 6 
A 1 1 
A 1 2 
B 0 2 
B 0 4 
B08b 
C 0 1 
C 0 7 
C 0 8 
C 1 2 
Size <#bp) 
4 2 1 
4 2 8 
9 4 
182 
3 2 2 
4 2 1 
4 2 1 
322 
4 2 1 
2 5 0 
322 
3 8 9 





















1AAGAAAT UG 1 GGAG 1 1A 1ACAAIGGGCCICAI i ICICIAAGAGAAC AAACAGAC 1AA1 1 CA 1 G1 G 1 C 1 1 1AAAA 1 CAAGGCCAA1AII 1 11AAGGGAA 




TAAGAAATGGlGGAG ,nA'lACAAlGAGCC"!CA'n"IC1CAAAGAAAACAAACAGACIAAI I C A I U I U I C I 1 1AAAAI CAAGGCCAAAA11TT1 AAAGGAAA 





























APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued) 
Comparison 
A g e 
C 2 1 Day B 
C 2 IDay B 
C 2 1Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day B 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
> ^ * ^ •>> 
D01 










H 0 6 
A 0 6 
A 0 9 
B02 
B09 
C 0 4 
Ste© (#fop) 




3 2 3 
251 























ATC TGTTTATATATGAC CTC C AAG G ATC 
GATCAGACTTCCTTCCAGTTCTTCCAGTTTTCTGATTGAGACCATCTTTATGTACGAAACCTTAAAAAAAGAAGTAGTTTTAGGCAGGCAGTAAGAGGA 













































TATC TGTTTATATATG AC CTC C AAG G ATC 
APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued) 
Comparison 
A g e 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1Day C 
C 2 1Day C 
C 2 1Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 2 1 Day C 
C 1 0 
C11 
D 0 4 
D 0 6 
D 0 9 
E 0 2 
E 0 6 
E 0 8 
E09b 
E 1 0 
F 1 0 
G 0 2 
G 0 3 
G 0 6 
G 0 8 
H07b 
Size (#bp) 
2 8 4 
3 2 3 
2 5 1 
3 2 3 
4 1 9 
3 2 3 
3 2 3 
2 7 6 
4 1 3 
3 2 3 
2 5 0 
321 
3 2 3 
281 
3 2 0 



























































APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued) 
Comparison 
A g e 
C 2 1DavC 
C 2 1 Day C 
C 2 1Day C 
C 2 1 Day D 
C 2 1Day D 
C 2 1Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
Ouorj i 
H08 
H 0 9 
H11 
A 0 4 
A 0 9 
A 1 2 












3 2 3 









4 1 9 
Sscjtisjncss 
GATCATCATTTTCCTCTGAAGTCAGATGTTTTACCTGCAATTCCTGTGTTGTAAATACACCGGCAGTACAGCGCCAACACTTACCAATAAACACATCGC 






















































APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued) 
Comparison 
A g e 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1 Day D 
C 2 1DayD 
C 2 1 Day D 
C 2 1 Day D 
C 2 1DayD 
C 2 1DayD 




















































GAICAI IA IAAI IAAAIA IC IGAGIAAIGAGGCI ICCCACAI 1 C 1 GG 1 1 1 1 1 AAAAAC I A I A I C IGAI 1 1AACACC 1 C 1AAAAA1 IC I IC I IGCAICICAA 
TACCTTTGTTTAATCTGATATTTATAAAATTTCCTATGATACGTAATCAACAACGAATATAACTGTGGTTGAGTTCTGTACTTACAAATCATGTAAAACTA 
AAAAA 1 GG'I GGAG11A1 ACAA'I AGG1 CCCA 111 CCCAAAGAAAACAAACAGAC1AA1 CCA1G 1 G 1 C 1 1 1AAAA1 CAA 1 GCCAA1A 111 11AAAGGAAACA 





















































acyl-CoA synthetase long-chain family member 1 
actin, alpha 2, smooth muscle, aorta 
beta-actin 
ATP synthase FO subunit 6 
calnexin 
chaperonin containing TCP1, subunit 6A 
chaperonin containing TCP1, subunit 8 
mitochondrial DNA, cytochrome oxidase subunit II 
F07 putative ribosomal protein S3 
similar to coactosin-like 1 (dictyostelium) (LOC768420) 
dermatan sulfate proteoglycan decorin 
eukaryotic translation elongation factor 1 alpha 1 
eukaryotic translation initiation factor 4A, isoform 2 
mrna for tau-crystalin/alpha enolase 
fatty acid binding protein 4, adipocyte 
fibulin 5 
FC506 binding protein 9, 63 kDa 
fibronectin 1 
lumican 
mitochondrial ribosomal protein L27 
myosin heavy chain II, smooth muscle 
myosin light chain kinase telokin 
Mitochondrial DNA - NADH dehydrogenase subunit 4 gene 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10 , 42kDa, nuclear gene 
encoding mitochondrial protein 
PG-M mRNA for proteoglycan 
prohibitin 2 
clone 0058P0007G11 putative peroxiredoxin 1 variant 3 
ras homolog gene family, member A 
similar to ribosomal protein L3 (LOC771432) 
clone ChEST398a16 
clone 0058P0031 
similar to SEC61 gamma (LOC776639) 
splicing factor, arginine/serine-rich 1 
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1 






















































































< _ . 
SMC In-vitro 
WC SR 
copy it copy it 
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upregulated at 6month's & In-vitro in WC 
downregulated at 6rrionths & In-vitro in WC 





























mitochondrial 16S nbosomal RNA 
Actin, alpha 2, smoth muscle, aorta 
Beta-actin 
ATP synthase FO subunit 6 
clone ChEST751d6 
Cytochrome c oxidase subunit II 
Cytochrome c oxidase subunit II 
Destnn 
Eukaryotic translation initiation factor 1 variant 1 
Eukaryotic translation initiation factor 4A isoform 2 
Fibulm 5 
Lumican 
Myosin light chain kinase ortelokin 
Mitochondrial nbosomal protein L27 
Myosin, heavy chain II, smooth muscle 
Myoglobin 
NADH dehydrogenase subunit 1 
NADH dehydrogenase subunit 4 
Peroxiredoxin 1 variant 3 
Ribosomal protein L7 
Ribosomal protein L3 
Ribosomal protein small subunit 3A 
similar to SDF3 (LOC771608) 
clone 0063P0030D07 putative solute carrier family 25 











































































1-3 day In-vivo 
WC SR" 





















































upregulated at 1 day in WC 
downregulatedatlday mWC 
APPENDIX S Table 6: Genes Differentially Upregulated Exclusively at 6 Weeks and at 6 Weeks in WC Versus SR 





















actm, alpha 2, smooth muscle, aorta 
beta actm 
ATP synthase FO subunit 6 
chaperomn containing TCP1, subunit 8 
cytochrome c oxidase subunit I 
similar to coactosin-like 1 (dictyostelium) (LOC768420) 
eukaryotic translation initiation factor 4A, isoform 2 
eukaryotic translation initiation factor 5 
enolasel, alpha 
fatty acid binding protein 4, adipocyte 
fibronectm 1 
GNAS complex locus, transcript variant 2 
lumican 
myosin heavy chain 11, smooth muscle 
NADH dehydrogenase subunit 1 gene 
NADH dehydrogenase subunit 1 gene, mitochondrial DNA 
prohibitin 2 
clone 0058P0007G11 putative peroxiredoxin 1 variant 3 
ras homolog gene family, member A 
clone 0058P0057E07 ribosomal protein L32-like 
similar to ribosomal protein L3 (LOC771432) 
ribosomal protein S23,11 days enbryo whole body cDNA, RIKEN full-length enriched library 
i l t p l f l l l i similar to yeast ribosomal protein S28 
RPS3A ribosomal protein S3A 





S-phase kinase-associated protein 1 
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1 
alpha-tropomyosin gene, exons 9c, 9d, and complete cds, alternatively spliced 
vimentin 
1day 6weeks 






































































































































upregulated at 6weeks in WC 
downregulated at 6weeks in WC 





































BAC CH261-117C7 (WAG-65N20) 
mitochonrial genome 
Actm, alpha 2 smooth muscle, aorta 
Beta-actin 
Cyclin-dependent kinase inhibitor p27 Kip1 
Coactosin-like 1 
Cytochrome c oxidase subunit I 
Cytochrome c oxidase subunit II 
Cytochrome c (mitochondrial genome) III 
DEAD box polypeptide 5, RNA hehcase 
Eukaryotic elongation factor 1-alpha 1 
Eukaryotic translation initiation factor 1 
Eukaryotic translation initiation factor 4A isoform 2 
Enolase 1 alpha 
Gelsolin 
Heat Shock Protein 90 alpha 
Lumican 
Myosin, heavy chain II smooth muscle 
Myosin light chain kinase 
NADH dehydrogenase subunit 1 
NADH dehydrogenase subunit 4 
Ubiquinone 
Prohibitin 2 
Peroxiredoxin 1, variant 3 
Ribosomal protein L3 
Ribosomal protein L4 
Ribosomal protein L9 
Ribosomal protein S3A 
Spermidine/spermine N1-acetyl transferase 
Serpin peptidase inhibitor clade F alpha-2 
antiplasmin (clone ChEST14214) 































































6 weeks 6 months 
































6 months In-vivo 
WC copy SR 





































































upregulated at 6months in WC 
downregulated at Bmonths in WC 
